CN1150030C - Recombinant human alpha-fetoprotein and uses thereof - Google Patents

Recombinant human alpha-fetoprotein and uses thereof Download PDF

Info

Publication number
CN1150030C
CN1150030C CNB96192764XA CN96192764A CN1150030C CN 1150030 C CN1150030 C CN 1150030C CN B96192764X A CNB96192764X A CN B96192764XA CN 96192764 A CN96192764 A CN 96192764A CN 1150030 C CN1150030 C CN 1150030C
Authority
CN
China
Prior art keywords
cell
rhuafp
purposes
leu
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB96192764XA
Other languages
Chinese (zh)
Other versions
CN1179106A (en
Inventor
�޲��ء�A��Ĭ����
罗伯特·A·默吉塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merrimack Pharmaceuticals Inc
Original Assignee
Mattienix Research & Development Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/377,309 external-priority patent/US5965528A/en
Priority claimed from US08/505,012 external-priority patent/US6331611B1/en
Application filed by Mattienix Research & Development Inc filed Critical Mattienix Research & Development Inc
Publication of CN1179106A publication Critical patent/CN1179106A/en
Application granted granted Critical
Publication of CN1150030C publication Critical patent/CN1150030C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)

Abstract

In general, disclosed are methods of inhibiting autoreactive immune cell proliferation in a mammal, involving administering to the mammal a therapeutically effective amount of recombinant human alpha-fetoprotein or an immune cell anti-proliferative fragment or analog thereof; methods of inhibiting a neoplasm in a mammal, involving administering to the mammal a therapeutically effective amount of recombinant human alpha-fetoprotein or an anti-neoplasm fragment or analog thereof; and methods of cell culture, involving the use of a media containing recombinant human alpha-fetoprotein or a fragment or analog thereof.

Description

Recombinant human alpha-fetoprotein and uses thereof
The expression and the purification of alpha-fetoprotein the present invention relates to clone people; The method that is used for the treatment of autoimmune disease; Treatment of cancer and diagnostic method; And cell growth and cell culture.
Alpha-fetoprotein (AFP) is a kind of serum albumin, and high level is generally only arranged in fetal blood.Alpha-fetoprotein content higher in the adult blood is relevant with some cancer with the regeneration of liver.
Put it briefly, feature of the present invention is the pure substantially bioactive recombinant human alpha-fetoprotein that has, and it comprises one section sequence, and this sequence is same as amino acid/11-389 or its fragment of Fig. 1 (sequence 9) substantially; Amino acid/11 98-590 or its fragment of Fig. 1 (sequence 10); Amino acid/11 98-389 or its fragment of Fig. 1 (sequence 7); The aminoacid 390-590 of Fig. 1 (sequence 8); Aminoacid 266-590 or its fragment of Fig. 1 (sequence 11).
In another related fields, feature of the present invention is a kind ofly to have the recombinant human alpha-fetoprotein of biologic activity or the method for its fragment or its analog with insect cell production, and this method comprises
A) insect cell that a kind of conversion is provided (for example, meadow food noctuid (Spodoptera frugiperda)), it contains the recombinant DNA molecules of a coding human a-fetoprotein or its fragment or its analog, this molecule is operably connected with expression controlling elements, by the expression of these controlling elements instructor's alpha-fetoprotein or its fragment or analog;
B) cultivate cell transformed; With
C) reclaim human a-fetoprotein or its fragment or the analog that biologic activity is arranged.
In the parties concerned, feature of the present invention also is pure substantially human a-fetoprotein or its fragment or its analog of producing with any method that this paper discloses and contains the therapeutic combination of the pure substantially human a-fetoprotein (or its fragment or analog) that any expression system that useful this paper discloses produces.
On the other hand, feature of the present invention is the method for a kind of inhibition mammal (as, human patients) id reaction immune cell propagation, comprises to mammal drug treatment effective dose recombinant human alpha-fetoprotein or its immunocyte antiproliferative fragment or analog.This method is based on my discovery: the non-glycosylated recombinant human alpha-fetoprotein of producing in prokaryote (as escherichia coli) can be used for suppressing to come from mammiferous id reaction immunocyte.This immunocyte preferably includes T cell or B cell; And the recombinant human alpha-fetoprotein (or its immunocyte antiproliferative fragment or analog) that is used for this method is preferably produced at prokaryotic cell (as escherichia coli), and is nonglycosylated.
Again on the one hand, feature of the present invention is the method for the autoimmune disease of a kind of treatment mammal (as human patients), comprises recombinant human alpha-fetoprotein or its immunocyte antiproliferative fragment or its analog to mammal drug treatment effective dose.Described autoimmune disease is multiple sclerosis, rheumatoid arthritis, myasthenia gravis, insulin-dependent diabetes or systemic lupus erythematosus (sle).In other preferred embodiment, described autoimmune disease is acquired immune deficiency syndrome (AIDS) or the repulsion that relates to transplant organ, tissue or cell.The recombinant human alpha-fetoprotein that is used for described method is preferably produced at prokaryotic cell (as escherichia coli), and is nonglycosylated.In other preferred embodiment, described method also comprises the immunosuppressant to mammal administration effective dose, and this dosage is lower than the standard dose that only uses this immunosuppressant.Described immunosuppressant is cyclosporin, steroid, azathioprine, FK-506 or 15-deoxyspergualin preferably.In another kind of preferred embodiment, described method comprises to a kind of tolerance agent of mammal administration (tolerizing agent).The recombinant human alpha-fetoprotein that is used for described method preferably produces at prokaryotic cell (as escherichia coli), and is nonglycosylated.
According to the present invention, administration recombinant human alpha-fetoprotein (" rHuAFP ") (or its fragment or analog) may be a kind of effective prevention, treatment or the method for improving mammiferous autoimmune disease.For this point is described, the inventor confirmed the reorganization HuAFP that in prokaryotic expression system, produces effectively the suppressor T cell effect be to modify in the propagation of autoantigen although practical situation is this rHuAFP in the mode that is different from naturally occurring HuAFP.Up to the present, the application of natural HuAFP is subjected to the limitation of its non-availability always, and natural HuAFP obtains from limited umbilical cord and cord serum source by loaded down with trivial details purge process.Because the rHuAFP of biologic activity can be arranged with a large amount of preparations of recombinant DNA technology now, so, be feasible with rHuAFP treatment autoimmune disease at present.The application of rHuAFP is especially favourable, because also the unknown has the harmful side effect relevant with human a-fetoprotein, and it is believed that administration safely is heavy dose of.
On the other hand, feature of the present invention is compositions and the method that is used for prevention, treatment and diagnosing tumour, particularly cancer.Of the present invention this is based on inventor's following discovery on the one hand: the non-glycosylated recombinant human alpha-fetoprotein that produces in prokaryote (as escherichia coli) can be used for treating and diagnosing the mammal that suffers from tumor, particularly suffer from malignant tumor, as breast carcinoma or carcinoma of prostate, and by the mammal of other cancer due to the malignant cell hypertrophy, described cell can be expressed the receptor of being discerned by recombinant human alpha-fetoprotein.
On the one hand, feature of the present invention is to suppress the method for tumor in the mammal (as human patients), comprises recombinant human alpha-fetoprotein or its antitumor fragment or analog to mammal drug treatment effective dose.Described tumor is malignant tumor (as mastadenoma and prostate tumor) preferably; And described recombinant human alpha-fetoprotein produces in prokaryotic cell (as escherichia coli), and is nonglycosylated.In preferred embodiments, described tumor cell can be expressed a kind of receptor by recombinant human alpha-fetoprotein identification.Described tumor is normally such as the cancer of adenocarcinoma or sarcoma.In preferred embodiments, tumor effect is in such as estrogen or androgenic hormone hypertrophy.The administration recombinant human alpha-fetoprotein preferably can suppress the hypertrophy of mammalian tumor cell or kill these tumor cells.This method also comprises to mammal administration chemotherapeutics.
On the other hand, feature of the present invention is the tumorigenic method of a kind of prevention mammal, comprises to a kind of recombinant human alpha-fetoprotein for the treatment of effective dose of mammal administration.Recombinant human alpha-fetoprotein preferably produces in prokaryotic cell (as escherichia coli), and is nonglycosylated.
Another aspect, feature of the present invention is a kind of cytotoxin of heterozygosis, comprises the recombinant human alpha-fetoprotein (or its fragment or analog) that is connected with a kind of cytotoxic agent.The example of this cytotoxic agent includes, but are not limited to diphtheria toxin, diphtherotoxin, pseudomonas (Pseudomonas) exotoxin A; Ricin and other phytotoxin are as Agglutinin, modeccin, Volkensin, viscusin; Cholera toxin (producing) by vibrio cholera (Vibrio cholerae); So-called shiga-like toxin (producing) by escherichia coli and other enterobacteria; The heat labile enterotoxin of Salmonella (Salmonella); With the heat labile thermotoxin of escherichia coli.In other preferred embodiment, the agent of described cell disposition is non-protide.The example of this non-protide cytotoxic agent includes, but are not limited to anticarcinogen, as amycin, and α-emission radionuclide, as astatine, and β-emission nucleic, as yttrium.The cytotoxic agent of described hybrid cell toxin is to be connected with recombinant human alpha-fetoprotein by peptide bond, and this hybrid toxins is to produce by the hybrid DNA molecule of expressing genetic engineering.In other preferred embodiment, the cytotoxic agent of described hybrid cell toxin is an albumen; This cytotoxic agent and recombinant human alpha-fetoprotein are chemically conjugated.
In others, feature of the present invention be a kind of can with bonded recombinant human alpha-fetoprotein or its fragment or the analog that can detect ground mark that detects ground mark of human body tumour cell.Described molecule is preferably crossed with the active nucleus labelling, as technetium-99m, I-125, I-131 or indium.Other detectable labelling comprises, but be not limited to enzyme, fluorogen, or other can send can detected signal (as radioactivity, fluorescence, color) composition or chemical compound, or after this labelling is exposed to its substrate, send a kind of can detected signal, perhaps described can detected signal can be a kind of can be by a kind of epi-position of antibody recognition (for example, alpha-fetoprotein epi-position or specially introduce the epi-position of reorganization alpha-fetoprotein by the engineering means be as HA or myc epi-position).Described molecule preferably can be at malignant tumor (as mastadenoma, prostate tumor or cancer), this malignant tumor can express a kind of can be by the receptor of recombinant human alpha-fetoprotein (or its fragment or analog) identification.Usually, this reorganization alpha-fetoprotein produces in prokaryotic cell (as escherichia coli), and is nonglycosylated.
The recombinant human alpha-fetoprotein (or its fragment or analog) that can detect ground mark can be used for video picture in the body is carried out at the position of the tool tumor cell of human patients.Generally, this method comprises: a kind of recombinant human alpha-fetoprotein molecule (or its fragment or analog) that detects ground mark (a) is provided; (b) to this molecule of patient's administration; (c) allow described labelled molecule and the combination of described position, and unconjugated molecule is removed from described position; (d) image at the position of acquisition tool tumor cell.Described position is mammary gland or prostate preferably.In other preferred embodiment, described position includes but not limited to: hepatic tissue, lung tissue, spleen tissue, pancreatic tissue, cerebral tissue, lymphoid tissue or bone marrow.Described image preferably utilizes dynamic γ scintiphotograph method to obtain.
The recombinant human alpha-fetoprotein (or its fragment or analog) that can detect ground mark also can be used for diagnosing the method for the tumor in the mammal (as human patients).This method comprises: (a) allow biological sample contact with the recombinant human alpha-fetoprotein that can detect ground mark; (b) detection and the bonded labelling of sample when detected labelling is higher than background content, show that the patient has tumor.This method preferably comprised before described contact procedure and contains the biological sample of cell fixed and section, and was to be combined in the cell membrane part that is equivalent to cell with the bonded labelling of sample.In preferred embodiments, biological sample is from the mammary gland or the prostate of human patients.
The recombinant human alpha-fetoprotein (or its fragment or analog) that can detect ground mark also can be used for detecting in the body the in vivo method of tumor of mammal.This method comprises: (a) recombinant human alpha-fetoprotein of the detected ground mark of administration diagnosis effective dose; (b) detect existence with the bonded detectable label of mammalian tissues, labelled amount is higher than the background content place and shows in this mammalian body and have tumor.
In preferred embodiments, this method relates to the patient who suffers from breast carcinoma under a cloud, and described tissue is a mammary gland tissue.In other preferred embodiment, this method relates to the patient who suffers from carcinoma of prostate under a cloud, and described tissue is a prostata tissue.The recombinant human alpha-fetoprotein that can detect ground mark preferably is connected with active nucleus (as technetium-90), finishes by radiophotography (as dynamic γ scintigraphy) and detect step.
On the other hand, feature of the present invention be used in vivo, original position or vitro detection tumor or any expression can be by the test kits of the cell of the receptor of recombinant human alpha-fetoprotein (or its fragment or analog) identification.Generally, this test kit contain a kind of can be by the recombinant human alpha-fetoprotein of tumor identification, and this albumen can be crossed by detected ground mark.If described recombinant human alpha-fetoprotein is unlabelled, preferably contain and have detectable label second kind of reagent of (as radionuclide, as technetium 90, I-125, I-131 or indium) in the then described test kit.When described detectable label was enzyme, described test kit also comprised a kind of substrate that is used for this kind of enzyme.This test kit also comprises a kind of being used for detectable label and the reagent that is connected of reorganization alpha-fetoprotein.In another embodiment, described be used to detect tumor or any deleterious can express a kind of can be by the test kit of the cell of the receptor of recombinant human alpha-fetoprotein (or its fragment or analog) identification, comprise a kind of contain can the specific bond recombinant human alpha-fetoprotein reagent and a kind of containing can be by the reagent of the recombinant human alpha-fetoprotein of the detected ground mark of anti-human a-fetoprotein antibody specific bond.The recombinant human alpha-fetoprotein of described test kit is preferably produced in prokaryotic cell (escherichia coli), and is nonglycosylated.
Recombinant human alpha-fetoprotein is used for the treatment of with cancer diagnosis has lot of advantages.For example, rHuAFP directly can be delivered medicine to tumor sites.Reorganization HuAFP also can be chemistry definition and synthetic, and with a large amount of preparations of recombinant DNA technology, for example, use the disclosed method of this paper.In addition, different with the cancer chemotherapy and the radiotherapy of routine, the side effect that recombinant human alpha-fetoprotein causes is very little, these side effect as feel sick, vomiting and neurotoxicity.Therefore, the heavy dose of rHuAFP of administration safely.
Diagnostic method of the present invention is favourable, because this method can be diagnosed out tumor quickly and easily.For example, rHuAFP is particularly conducive to the realtime imaging of cancer as diagnostic agent (for example, radiating video picture by scintigraphy), so as to carry out cancer (as, breast carcinoma) the preceding or inner operation of operation is located and by stages, also is favourable in postoperative inspection.The application of this diagnostic method can be carried out non-invasive mensuration to existence, position or the shortage of tumor, and this helps the disease of monitored patient.
On the other hand, feature of the present invention be a kind of contain recombinant human alpha-fetoprotein or its cell stimulatory fragment or analog cell culture medium.Of the present invention this is based on inventor's following discovery on the one hand: the non-glycosylated recombinant human alpha-fetoprotein that produces in prokaryote (as escherichia coli) is a kind of cell proliferating agent, for example, and in external promotion bone marrow growth.This recombinant human alpha-fetoprotein preferably produces in prokaryotic cell (escherichia coli), and is nonglycosylated.
Therefore, this feature on the one hand of the present invention is a kind of cell culture processes, and this method comprises that (a) provides a kind of cell culture medium that contains recombinant human alpha-fetoprotein; (b) provide a kind of cell; (c) in described culture medium, cultivate described cell, make cell proliferation and keep.Described cell is mammalian cell preferably.The example of this mammalian cell comprises medullary cell (for example, T cell, natural killer cell, lymphocyte), hybridoma or genetically engineered cell system.The example of other cell comprises hematopoietic cell, as stem cell, blast cell, CFU-GM (for example, such as the erythrocyte CFU-GM that becomes burst forming unit and colony forming unit), myeloblast, macrophage, mononuclear cell, macrophage, lymphocyte, the T-lymphocyte, the B-lymphocyte, eosinophil, basophil, tissue mast cell, megalokaryocyte [for example, referring to " the best Taylor ' s physiological Foundations of medical practice " (Best and Taylor ' sPhysiological Basis of Medical Pratice), John B.West work, Willians ﹠amp; Wilkins, Baltimore].In other preferred embodiment, this method relates to the cell culture of ex vivo.
On the other hand, feature of the present invention is to suppress the method for the myelotoxicity of mammal (as human patients), comprises to a kind of recombinant human alpha-fetoprotein or its bone marrow toxicity inhibitory analogues or fragment for the treatment of effective dose of animals administer.Described recombinant human alpha-fetoprotein preferably produces in prokaryotic cell (escherichia coli), and is nonglycosylated.
On the other hand, feature of the present invention is a kind of method that mammal medullary cell propagation suppresses that suppresses, and this method comprises to the reorganization alpha-fetoprotein of mammal administration effective dose or its anti-fragment or analog of suppressing.Recombinant human alpha-fetoprotein preferably produces in prokaryotic cell (as, escherichia coli), and is nonglycosylated.
On the other hand, feature of the present invention is a kind of method that promotes mammal medullary cell propagation, comprises recombinant human alpha-fetoprotein or its cytositimulation fragment or analog to mammal administration effective dose.Recombinant human alpha-fetoprotein preferably produces in prokaryotic cell (as escherichia coli), and is nonglycosylated.
On the one hand, feature of the present invention is a kind of method of preventing mammal medullary cell transplant rejection again, comprises recombinant human alpha-fetoprotein or its anti-fragment or analog of repelling to mammal administration effective dose.Recombinant human alpha-fetoprotein preferably produces in prokaryotic cell (as escherichia coli), and is nonglycosylated.According to method of the present invention, administration rHuAFP (or its fragment or analog) promotes and intensive aspect is outer, ex vivo or cells in vivo are grown effective ways.In addition, administration chemical compound of the present invention may still prevent, treats or improve the toxemic effective ways of mammiferous bone marrow.
With rHuAFP (or its fragment or analog be favourable as the main component of tissue culture medium (TCM), almost do not have because its advantage is the probability of pathogen infection).
" human a-fetoprotein " be meant a kind of substantially with the polypeptide of the aminoacid sequence of [" institute of NAS periodical " (Proc.Natl.Acad.Sci., USA) 80:4604 (1983)] human a-fetoprotein gene encoded protein of describing by Morinaga etc.The method that produces human a-fetoprotein in prokaryotic cell is disclosed in United States Patent (USP) 5,384, in 250, and also consistent with the disclosed method of this paper.
" expression controlling elements " are meant a nucleotide sequence, and it comprises the recognition sequence about the factor of controlling the albumen coded sequence expression and being operably connected with this sequence.Therefore, express controlling elements and generally include the sequence that control is transcribed and translated, for example, promoter, ribosome binding site are put, repressor binding site and activator binding site.
" identical substantially aminoacid sequence " is meant a peptide species, and the homology of the aminoacid sequence of it and naturally occurring human a-fetoprotein is at least 80%, typically be at least about 85%, more typically be at least about 90%, often be at least about 95%, more frequent is to be at least about 97%.The length of comparative sequences is at least about 16 aminoacid usually, is at least about 20 aminoacid usually, more generally be to be at least about 25 aminoacid, typically be at least about 30 aminoacid, preferably more than 35 aminoacid.
The homology of polypeptide generally is to measure with sequence branch preface software (for example, the sequence analysis software bag of Cheng Sikang star university biotechnology center, 1710, University Avenue, Madison, WI 53705).Analysis of protein software matches to similar sequences by estimating with the homology degree of various displacements, disappearance, displacement and other modification.Conservative substitution generally comprises the displacement in following each class range: glycine, third amino; Valine, isoleucine, leucine; Aspartic acid, glutamic acid, agedoite, glutamine; Serine, threonine; Lysine, arginine; And phenylalanine, tyrosine.
In this article, " pure substantially " is meant a kind of albumen of natural with it the component separating that accompanies or the albumen of polypeptide.Generally, when the total protein of 60-75% all was protein of interest at least in a kind of sample, this protein of interest was pure substantially.Little modification or chemical modification generally have identical peptide sequence.Pure substantially albumen generally contains this albumen that surpasses about 85-90% in sample, and preferred purity is more than 99%.Generally, purity is on the chromatographic column, measure on the polyacrylamide gel, or by the HPLC assay determination.
When a kind of albumen with under native state with it when the impurity of association separates mutually, this albumen is exactly the albumen that does not have natural association composition substantially.Therefore, the albumen of chemosynthesis or the albumen that produces in the cell system that is different from this proteic cell of natural generation will be not have its natural association composition substantially.Therefore, this term can be used for being described in synthetic Eukaryotic polypeptide and the nucleic acid of coming from escherichia coli or other prokaryote.
The invention provides pure substantially human a-fetoprotein.Can be partly according to the 26S Proteasome Structure and Function characteristics design of human a-fetoprotein go out various from biomaterial the method for separation of human alpha-fetoprotein (AFP).In addition, can will resist AFP antibody to be fixed on the solid matrix, to obtain a kind of single-minded affinity of height that is used for purification people AFP.
Except the polypeptide of total length substantially, the present invention also provides bioactive recombinant fragment of having of human a-fetoprotein or analog.The fragment that part combination or immunosuppressive activity for example, are arranged.
The desirable segmental natural or synthetic DNA fragment of coding human a-fetoprotein or its will be incorporated on the dna structure, this dna structure can the transfered cell culture in and express therein.Generally include an origin of replication that can be utilized by host cell for importing dna structure that this host prepares, the dna fragmentation of the required part of a coding human a-fetoprotein, operationally be connected with this alpha-fetoprotein encode fragment transcribe and translation initiation is regulated sequence, and transcribing and translation termination adjusting sequence of operationally being connected with the alpha-fetoprotein encode fragment.This transcriptional regulatory sequences generally includes one can be by the allogeneic promoter of host's identification.The host is depended in the selection of suitable promoter, but under appropraite condition, can use such as trp, tac and phage promoter, tRNA promoter and glycolytic ferment promoter (work such as Sambrook, " molecular cloning: experiment guide " (Molecular Cloning:Laboratory Manual), Cold Spring HarborPress, Cold Spring Harbor, NY 1989).May wish to comprise suitable localized recognition sequence (for example, colibacillary lac repressor) in some occasion about can in host cell, regulating the factor of transcribing.Can use and comprise dubbing system and transcribe and translate the adjusting sequence and be usually used in inserting the commercially available expression vector that coding is treated the dna fragmentation of expressing gene.
Above-mentioned various promoter, transcribe and generally be meant " expression controlling elements " with translation sequences.
Also the dna fragmentation of an all or part of people AFP of coding can be incorporated in the host cell chromosome.
Can change in the host cell with the carrier that well-known method will contain interested dna fragmentation, these methods are because of the type of cell host different (Sambrook etc., the same).The implication of " cell transformed " this saying also comprises the filial generation of transformant.
The prokaryotic hosts that can be used for the high level expression recombiant protein comprises: the various bacterial strains that escherichia coli, bacillus subtilis (Bacillus Subtilis) and false unit cell belong to.
Method of the present invention provides a kind of means that produce the human a-fetoprotein of a large amount of biologically actives.With the AFP biologically active of the inventive method production, although in fact this AFP is not modified in the mode identical with naturally occurring people AFP.
" immunocyte antiproliferative " this saying is meant the growth that can suppress unwanted immunocyte (for example, the id reaction T cell that uses the disclosed analytical method of this paper to record).
" tumor " is meant the obnoxious growth of the cell of any no physiological function.Generally, tumor cell disengages from its normal cell division control, promptly so a kind of cell, and its growth is not to be regulated by biochemistry common in the cellular environment and physical influence.As a rule, the propagation of tumor cell can form the clone of cell, and this clone is benign or virulent.The example of tumor include, but are not limited to transform with immortalized cell, tumor and cancer, as mammary glandular cell cancer and carcinoma of prostate.
" treatment effective dose " this saying is meant that can suppress tumor proliferation maybe can suppress the non-glycosylated recombinant human alpha-fetoprotein of id reaction immune cell propagation or irritation cell (as medullary cell) propagation or the dosage of its antitumor fragment or analog.
" diagnosis effective dose " this saying is meant and can be in the target site of mammal (as human patients) can detected warp can detects the recombinant human alpha-fetoprotein of ground mark or it is through detecting the fragment of ground mark or the dosage of analog.
" cytositimulation " this saying is meant increases cell proliferation, increase cell division, promote cell differentiation and/or growth or prolong cell survival.
" bone marrow toxicity inhibition " is meant that suppressing bone marrow peels off.
Can understand other features and advantages of the present invention from following explanation and claims to the preferred embodiment of the invention.
Accompanying drawing is described earlier.
Accompanying drawing
Fig. 1 is nucleotide sequence (sequence 4) and the deduction aminoacid sequence (sequence 5) of the cDVA of coding human a-fetoprotein.
Fig. 2 is that 10% SDS-PAGE of rHuAFP fragment I (sequence 11) analyzes (swimming lane A, molecular weight marker; Swimming lane B, natural human alpha-fetoprotein (AFP); Swimming lane C, unpurified rHuAFP; Swimming lane D, rHuAFP fragment I; With swimming lane E, rHuAFP (amino acid/11 of Fig. 1-590, sequence 5)).
Fig. 3 rHuAFP that to be expression produced by escherichia coli and domain fragment are to people's " inhibiting rectangular histogram of AMLR (AMLR).
Fig. 4 represents with the purity of the rHuAFP that is produced by baculovirus and escherichia coli of polyacrylamide gel electrophoresis and column chromatography preparation and a series of diagrammatic sketch of biochemical character.Fig. 4 A is 10% non-degeneration alkalescence polyacrylamide gel, shows the purity of rHuAFP.Mice amniotic fluid albumen (transferrin, AFP and albumin) is shown in swimming lane 1, and natural HuAFP (swimming lane 2) is by the rHuAFP (swimming lane 3) of baculovirus generation and the rHuAFP (swimming lane 4) of escherichia coli generation.Fig. 4 B is 10% sodium dodecyl sulfate polyacrylamide gel, shows the purity of the rHuAFP that produces with baculovirus and escherichia expression system.Molecular weight marker is shown in the swimming lane 1, and natural HuAFP, the rHuAFP that is produced by baculovirus and escherichia coli are shown in respectively in swimming lane 2,3 and 4.A series of FPLC chromatograms of the rHuAFP that Fig. 4 C is the natural HuAFP of eluting on Mono Q anion-exchange column, produced by baculovirus and escherichia coli.The rHuAFP (being respectively chromatogram 2 and 3) that eclipsed chromatogram is represented natural HuAFP (chromatogram 1), produced by baculovirus and escherichia coli.Fig. 4 D is by allowing natural HuAFP of 50 μ g and rHuAFP pass through from reverse Delta Pak C18 post (Waters), and be used in 0.1% " trifluoroacetic acid " (TFA) in the 0-100% acetonitrile gradient eluting of preparation and a series of HPLC chromatograms of obtaining.Eclipsed chromatogram is represented natural HuAFP (chromatogram 1) and the rHuAFP (being respectively chromatogram 2 and 3) that is produced by baculovirus and escherichia coli.
Fig. 5 is a rectangular histogram, and the anti-natural HuAFP antibody that its expression is produced by the rHuAFP that produces with baculovirus and escherichia expression system stops the immunosuppressant of AMLR.The immunosuppressant that is produced by the rHuAFP that produces with baculovirus and escherichia expression system is significant (P＞0.002), and produce by the natural HuAFP of monoclonal anti (aAFP) antibody, also be significant (P＜0.03) by the immunosuppressant of the AMLR of rHuAFP mediation.AMLR cultivates being with or without under the proteic condition and sets up, and it contains 2 * 10 5Individual effector T cell, 2.5 * 10 5Self non-T cell of individual radiation, results in the time of 144 hours, and according to mixing in the id reaction T cell 3The H-thymidine is to measure himself propagation.Self inhibited proliferation of rHuAFP is performed such: the extension rate with 1/8 (125 μ g/ml) adds mouse-anti people AFP monoclonal antibody in the AMLR culture, rHuAFP (blank bar) inhibition that rHuAFP (hatched bars) that AMLR can be produced by baculovirus by 100mg/ml and 100 μ g/ml are produced by escherichia coli.Control cultures is made up of the AMLR that has 1/8 times of anti-people AFP (aAFP) monoclonal antibody to exist.
Fig. 6 is a series of rectangular histograms (Fig. 6 A and 6B), and expression personnel selection AMLR (Fig. 6 A) and " peripheral blood lymphocyte " is (Fig. 6 B) immunosuppressive effect of being mediated by rHuAFP when testing (PBL).Fig. 6 A represents to carry out AMLR (AMLR) result that it cultivates preparation by the non-T lymphocyte to 250,000 T cells and equivalent self radiation (autologous irradiated).Come from the reorganization HuAFP preparation of system of escherichia coli and baculovirus expression and albumin when cultivating beginning all the concentration with 100 μ g/ml add.In the time of 144 hours, pass through 3H-thymidine incorporation is measured multiplication effect.Fig. 6 B represents the PBLs (2 * 10 with the stimulation of 1 μ g/ml concanavalin A (ConA) 5) the result, it was cultivated 48 hours in only being supplemented with the albuminous RPMI culture medium of 2mg/ml.Concentration with 100 μ g/ml adds albumin and the rHuAFP that comes from escherichia coli and baculovirus, begins to cultivate.In the DNA building-up process 3The incorporation of H-thymidine is measured cultivation effect.Record SEM sub-average 5%.
Fig. 7 is the plasmid figure of pVT-PlacZ.
Fig. 8 is a series of drawing, and expression rHuAFP is to dynamic (dynamical) inhibition effect (Fig. 8 A) of T cell activation and the rHuAFP dose-effect relationship to the T cell of self propagation.Fig. 8 A is illustrated in not have rHuAFP () and figure with cell culture multiplication effect of time more than 4 days is arranged under the condition that 100 μ g/ml () rHuAFP exist.The effector lymphocyte group's of () expression single culture background propagation.In the above-mentioned time, the inhibitory action to AMLR that is mediated by reorganization HuAFP-is significant (P＜0.01).Fig. 8 B is that consumption is the T cell inhibiting effect of rHuAFP to self breeding of 6-100 μ g/ml () when being illustrated in 144 hours.() be illustrated in the contrast effect of reacting under the protein free condition.Effect is significant (P＜0.005) to the rHuAFP of consumption in 12.5-100 μ g/ml scope to id reaction T cell inhibiting.
Fig. 9 is expression rHuAFP is paved with the influence of back growth to the MCF-7 breast cancer cell of estrogen stimulation a rectangular histogram.
Figure 10 is illustrated in the propagation of Os Mus marrow in serum-free RPMI culture medium under the existence condition that is with or without 400 μ g/ml rHuAFP and 5 μ g/ml transferrins.
The expression of recombinant human alpha-fetoprotein
The structure in CDNA library
Use the poly (A) that separates by in the liver cell (～3g weight in wet base) of human aborted fetus of 4.5 monthly ages+Size fractionation cDNA (0.5-3kg) the construction cDNA library of RNA preparation. (in addition, can be from Clontech Laboratory, Inc. obtains fetus cDNA library, Palo Alto, CA.). With guanidine thiocyanate method (Chirgwin etc., " biochemistry " be 18:5294 (Biochemistry), 1979) prepare total RNA, and by oligo (dT)-cellulose chromatography (Collaborative Research, Bedford, MA) [" modern molecular biology scheme " (Current Protocols in Molecular Biology), Ausubel etc., work, Wiley Interscience, New York 1989] screening mRNA. Utilize Librarian II cDNA synthetic agent box (Invitrogen, San Diego, (A) synthetic cDNA and carry out classification at 1% Ago-Gel and separate. Extract the fragment of 0.5-3kb, and it is connected Invitrogen with carrier pTZ18-RB) connection, then use its transformed competence colibacillus Escherichia coli DH1 α F ' (Invitrogen)). With Colony/Plaque Screen filter membrane (DuPont, Wilmington, DE) carry out bacterium colony molding (colony lifts), in the solution that contains 0.5M NaOH, 1.5M NaCl, cultivate 10 minutes bacterial clumps to transfer and carry out cracking and sex change. The washing filter membrane is 5 minutes in the solution that contains 1.5M NaCl, 0.50M Tris-HCl (pH7.6), and is then air-dry. Then in chloroform, filter membrane is washed 5 times, in 0.3M NaCl, soak to remove the cell bits, then air-dry. By DNA being fixed on the nitrocellulose filter under vacuum condition, baking 2 hours under 80 °. The filter membrane that baked is placed in the solution that contains 6 * SSC (1 * SSC=150mM NaCl, 15mM natrium citricum [pH7.0]), 1 * Denhardt ' s solution (0.2g/l polyvinylpyrrolidone, 0.2g/l " bovine serum albumin(BSA) " (BSA), 0.2g/l Ficoll 400), 0.05% sodium pyrophosphate, 0.5% SDS and 100 μ g/ml e. coli dnas, 37 ℃ of lower prehybridizations 3 hours. In same solution, hybridizing 18-24 hour under 37 ℃, without SDS, contain 1-2 * 10 in the hybridization solution6Cpm/ml by 5 '-end phosphorylation " [modern molecular biology scheme " (Current Protocols in Molecular Biology), the same] use32Two kinds of oligonucleotides of P mark. Sequence for detection of the oligonucleotides in described library is: 5 '-TGTCTGCAGGATGGGGAAAAA-3 ' (sequence 1) and 5 '-CATGAAATGACTCCAGTA-3 ' (sequence 2), respectively corresponding to 772-792 and 1405-1422 position of people AFP coded sequence. Under 37 ℃, with 6 * SSC, 0.05% sodium pyrophosphate filter membrane was washed twice, 30 minute, then in same solution, washed once 30 minutes under 48 ℃. Under the condition that has Du Pont Cronex Lightning Plus intensifying screen to exist, with dry filter membrane Kodak XAR film was exposed 24-48 hour, to identify positive colony. Separation, amplification positive colony, and carry out Southern engram analysis [" modern molecular biology scheme " (Current Protocols in Molecuar Biology), the same]. Say simply, with the DNA of suitable restriction enzyme hydrolysising purification, and the fragment of resulting separation on 1% Ago-Gel. Then DNA is transferred on the nitrocellulose filter. Hybridization conditions as mentioned above, difference is except above-mentioned two kinds of probes, also to use the third32The oligonucleotides of P mark (5 '-CATAGAAATGAATATGGA-3 ' (sequence 3), the 7-24 position of expression people AFP encode fragment). In 3,000 bacterium colonies that screen, identify 5 positive colonies. One of them clone pLHuAFP is used to the structure of the following stated.
Make up total length people AFP cDNA
Prepare with following 5 dna fragmentations and a kind ofly to contain translation initiation codon, be the structure of people AFP coded sequence and translation stop codon thereafter.
Fragment 1: with two kinds of non-phosphorylating oligonucleotides annealing, to form a kind of double chain DNA molecule, it consists of: one 5 '-end viscosity EcoRI recognition site, be an ATG initiation codon subsequently, and front 60 base-pairs (bp) of people AFP cDNA. And comprise PstI restriction site (in this scheme, nucleotides 1 is first nucleotides of first codon (Thr) of maturation protein, is equivalent to the nucleotides 102 of Morinaga etc., and is the same) on the 60th that is arranged in this coded sequence. With this fragment with EcoRI and the linearizing pUC119 of PstI (have the pUC19 from the intergenic region of 5465 HgiAI to 5941 AhaII of M13, this intergenic region is inserted in the NdeI site of pUC19) connection. Resulting DNA is amplification in Escherichia coli NM522 (Pharmacia, Piscataway, NJ). Reclaim the EcoRI-PstI Insert Fragment with following method: the enzymatic digestion recombinant plasmid, then carry out electrophoretic separation at 5% polyacrylamide gel, in gel, extract again.
Fragment 2: by the people AFPcDNA fragment (57-153) with PstI and NsiI digestion pLHuAFP and a 97bp of above-mentioned gel-purified acquisition. This clone contains the complete encode fragment and 5 of people AFP ' and 3 ' non-translated sequence.
Fragment 3: by the people AFP cDNA fragment (150-373 position) with NsiI and AlwNI digestion pLHuAFP and a 224bp of above-mentioned purifying acquisition.
Fragment 4: by the people AFP cDNA fragment (371-1692 position) with AlwNI and StyI digestion pLHuAFP and a 1322bp of above-mentioned purifying acquisition.
Fragment 5: with two unphosphorylated oligonucleotides annealing, form the double-stranded DNA of 86bp, it contains 1693 to 1773 the people AFP sequences that stop the TAA terminator codon of AFP encode fragment from the StyI site, and its back is a viscosity BamHI site. Need not any further operation and can use this synthetic DNA.
Thoroughly be hydrolyzed pBlue Script (StrataGene, La Jolla, CA) with EcoRI and BamHI, and its adding contained in the connection mixture of above-mentioned 5 kinds of purifying fragments. Contrast connects in the mixture and only contains linearizing pBluescript. Above-mentioned two kinds parts that connect mixture are used for transformed competence colibacillus bacillus coli DH 52 (GIBCO/BRL, Grand Island, NY). From several transformant, separate recombinant plasmid, screen by deep Restriction Enzyme analysis and dna sequencing. Filter out a kind of recombinant plasmid and called after pHuAFP. Subsequently it is used for people AFP gene is inserted in several expression vectors. PHuAFP comprises the EcoRI-BamHI fragment of a uniqueness, this fragment not only comprises 5 '-terminal ATG initiation codon and 3 '-terminal TAA terminator codon, but also contain the complete coded sequence of people AFP.
The AFP expression vector
In 3 kinds of different expression systems, successfully realized the synthetic people AFP of high level in Escherichia coli. The TRP system can directly express. R * l system can produce a kind of fusion, and it contains 20 by the amino acid of trpE and carrier sequential coding. The AFP that the maltose-binding protein of MAL system expression and malE gene outcome-a kind of 42kd merges.
TRP expression system: the 1186bp EcoRI-Bam HI AFP encode fragment of pHuAFP is cloned into expression vector pTrP4 (Olsen etc., " biotechnology magazine " be g:179 (J.Biotechnol.), 1989) on, the clone is positioned at the downstream of the ribosome bind site of trp promoter and a modified.
Say simply, with EcoRI and BamHI digestion pHuAFP, and with the Klenow polymerase with end-filling. Then the AFP fragment of 1186bp is carried out gel-purified. Digest pTrp4 with ClaI, use the Klenow polymerase with its end-filling, and linearizing carrier is carried out gel-purified. The AFP fragment and the pTrp4 main chain that connect 1186bp, and use it for the transformed competence colibacillus Escherichia coli, i.e. following bacterial strain: DH5 α, BL21 (F.W.Studier, Brookhaverc National Laboratory, Upton, preserving number 39627), SG928 (ATCC NY), SG927 (American Type Culture Collection, Rockville, MD:, preserving number 39628) and SG935 (ATCC, preserving number 39623).
R * 1 expression system: people AFP cDNA is cloned into expression vector pR * 1[Rimm etc., " gene " (Gene), 75:323,1989] near the position of trp promoter, it is arranged in the TrpE translation box. By with EcoRI and BamHI digestion people AFP cDNA being excised from pHuAFP, and be cloned on pR * I (BioRad Laboratories, Hercules, CA) through suitable processing. Then with the above-mentioned coli strain of plasmid thaumatropy that is called as pR * 1/HuAFP and the CAG 456 (D.W.Cleveland, Johns Hepkins University, Baltimore, MD) that finally obtain.
MAL expression system: AFP cDNA is inserted among the expression vector pMAL (New England Biolabs, Inc., Beverly, MA), be placed under the control of tac promoter, and be arranged in the MalE translation box. Say simply, be hydrolyzed pHuAFP with BamHI, and with the Klenow polymerase with end-filling. Disengage by the remainder of EcoRI digestion with people AFP cDNA DNA, then carry out gel-purified. The method section of purifying is connected on the suitable pMAL-C that digested. The recombinant plasmid of correct orientation-its name is called pMAL/HuAFP is used for transforming bacillus coli DH 52, TBI (New England Biolabs) and SG935.
To checking order for the AFP encode fragment that makes up above-mentioned 3 kinds of expression systems, find the AFP of its coding complete length.
At expression in escherichia coli AFP
Under 30 ℃ or 37 ℃, aeration condition, bacterial cultures is cultivated. The culture of Escherichia coli of spending the night is grown having replenished in suitable required antibiotic (tetracycline-HCl 50 μ g/ml, ampicillin-Na 100 μ g/ml) and the LB culture medium.
TRP and R * 1 expression system: under the tryptophan starvation conditions, induce the trp promoter. Induce is to carry out in the MgCA culture medium of as follows preparation: with 1g casamino acid (Difco Laboratory, Detroit, MI), 6g Na2HPO 4，3gKH 2PO 4，0.5g NaCl，1gNH 4Cl adds in 1 liter of Milli-Q water (Millipore company, Bedford, MA), pH is transferred to 7.4, and this solution is carried out autoclaving. Make in the culture medium of cooling and contain 2mM MgSO4、0.1mM CaCl 2, and 0.2 % glucose. To dilute 100 times by the culture of overnight incubation in having replenished antibiotic MgCA, then making Growth of Cells under 30 ℃ is 0.4 to A550, centrifugal results, and under-20 ℃, preserve with precipitation form.
The MAL expression system: (IPTG) induces the tac promoter with the gratuitous inducer isopropylthio-β-D-galactoside. With having replenished antibiotic LB culture medium with 100 times of overnight culture dilutions, and to make cell grow to A550 under 37 ℃ be 0.4. Then IPTG being added to final concentration is 0.3mM, and bacterium was cultivated 2 hours again. By centrifugal cell harvesting, and in-20 ℃ of lower precipitations of preserving.
Detect the AFP Expression in Escherichia coli
Analyze and research to measure expression and the behavior of recombinant AFP. Perhaps cell precipitation is suspended in SDS-cracked solution (0.16M Tris-HCl[pH6.8]), 4% W/VSDS, 0.2m dithiothreitol (DTT) (DTT), 20% glycerine, 0.02 bromophenol blue) in, boiled 5 minutes, and be used for SDS-PAGE and analyze; Perhaps cell precipitation is suspended in by 10mM Na2HPO 4, 30mM NaCl, in the lysis buffer that 0.25% Tween20,10mM EDTA, 10mM ethylene glycol bis (second-amino ether) tetraacethyl (EGTA) form, under 4 ℃, cultivated 30 minutes with the 1mg/ml lysozyme, then with the power of 50 % with pulse mode (" sonics and equipment " (the Sonics and Materials) that carried out sonication 3 * 1 minutes, Danbury, CT:model VC300 Sonifier). Under 10,000g, with centrifugal 20 minutes of lysate, will contain in another test tube of supernatant impouring of soluble protein, and lower freezing stand-by at-20 ℃. To contain the precipitation Eddy diffusion of insoluble protein in the SDS-lysis buffer, boil 5 minutes, and-20 ℃ of usefulness such as lower preservation. To being released in that total protein in the SDS-lysis buffer and solubility and precipitation fraction carry out that SDS-PAGE analyzes and Western inhales immune detection after the seal transfer. In above research, use videodensitometer (BioRad, Model620) that the gel of Coomassie blue stain is carried out conventional sweep. Can carry out quantitative assay to the recombinant AFP amount that produces thus, represent with the percentage form that accounts for total protein of cell.
The purifying of the AFP that in the TRP system, expresses
Except as otherwise noted, all operations all carries out under 4 ℃. Obtain freezing cell precipitation Eddy diffusion in 25ml lysis buffer A[50mM Tris-HCl[pH7.5 with every part from 1 liter of culture]], 20 % sucrose, 100 μ g/ml " phenylmethylsulfonyl fluoride " (PMSF)] in, and incubation 10 minutes. Add EDTA to final concentration be 35mM, and extract was placed 10 minutes again. Add 25ml (lysis buffer B (50mM Tris-HCl[pH7.5]), 2.5mM EDTA, 0.2% TritonX-100) after with lysis buffer incubation 30 minutes again. In 12,000g centrifuge cell lysate 20 minutes, and will contain the washing of precipitate 2 times of recombinant AFP with 50ml lavation buffer solution (50mM Tris-HCl[pH8.0], 10mM EDTA, 0.2% Triton X-100), all carry out above-mentioned centrifugal after each washing. Precipitation is dissolved in 50ml sex change buffer solution (0.1M K2HPO4[pH8.5]), 6M guanidine hydrochloride, 0.1M2-mercaptoethanol) in, then sonication mixed 4 hours at a Nutator (Clay Adams). With the solution that contains 50mM Tris-HCl, 100mM NaCl, 1mMEDTA the extract that dissolves is diluted 50 times, and made the recombinant AFP protein renaturation 24 hours. These 50 times of dilution step are very important, because as if AFP has little accumulation before dilution. Through dilution with after concentrating, AFP no longer builds up again. On the YM10 film, mentioned solution is concentrated 100 times with the Amicon filter, and by the clarification of Millex 0.22 μ m molecular filter (Millipore). At room temperature be used on the Mono Q post (Pharmacia) of balance among the 20mM Tris-HCl (pH8.0) and be further purified AFP, with linear gradient 0-100% 1M NaCl, the albumen of 20mM Tris-HCl (pH8.0) elution of bound. By SDS-PAGE, alkaline PAGE (APAGE) and Westem engram analysis elutriated fraction.
The aforementioned polypeptides expression also can be used for producing with the conventional method of purifying and separates useful human a-fetoprotein or analog (as mentioned below).
Polyacrylamide gel electrophoresis and Western immunologic detection method
Method (" gel electrophoresis of protein: a kind of practical approach " (Gel Electrophoresis of Proteins:A Practical Approach) according to Hames etc., IRL Press, London, 1981), use mini-Protean electrophoretic apparatus (BioRad) in discontinuous buffer system, to carry out SDS-PAGE and alkaline PAGE. After SDS-PAGE or APAGE, by gel being immersed in the transfering buffering liquid (12.5mMTris-HCl, 96mM glycine, 20% methyl alcohol [pH8.2]) 15 minutes, rhAFP is carried out immune detection. Then cover an Immobilon polyvinylidene fluoride (PVDF) film (Millipore) at every clotting glue, and its two electrodes that are clipped in mini-Protean transfer device (BioRad) are carried between the net, make gel near negative electrode. This system is immersed in the transfering buffering liquid, apply the electric current of 150mA, act on 2 hours. Unreacted site 1 hour on the sealing Immobilon pvdf membrane in the solution that contains 20mMTris-HCl (pH7.5), 500mM NaCl, 3% gelatin. The anti-human AFP antiserum of rabbit of respectively same alkaline phosphatase (BioRad) being puted together and goat anti-rabbit antibody are as firsts and seconds antibody. Active with 5-bromo-4-chloro-3-indyl phosphate and P-nitroblue tetrazolium (BioRad) detection of alkaline phosphatase.
It is quantitative that AFP expresses
Employment AFP " enzyme linked immunosorbent assay (ELISA) " is kit (Abbort Laboratories, Chicago, IK) (ELISA), and rhAFP is carried out quantitatively.
Dye gel determination AFP output by scanning silver. When with having adopted " tryptophan " (Trp) during the Plasmid Transformation SG935 cell of the coding AFP of expression system, AFP accounts for the 2-5 % (containing approximately 3-7mg AFP in every liter of culture) of Bacillus coli cells total protein. As mentioned above, the most of AFP in the primary extract is insoluble. Above-mentioned again course of dissolution can reclaim that 50-60% is stable, the AFP (per 201 Escherichia coli approximately can get 50mg) of half purifying, monomeric form. Can be further purified above-mentioned product, to obtain the purifying monomer A FP of 25mg.
The N-terminal analysis
Carry out automatic edman degradation with a Porton albumen/peptide gas phase microsequencing instrument, with an integrated micropore HPLC optimization customized. With the inner option program auxiliary protein sequence analysis of PC/Gene software kit (Intelligenetics).
Carry out clone, expression and the purifying of HuAFP with a kind of baculovirus expression system
Recombinant baculovirus according to standard method well known in the art (for example, referring to U.S. Patent No. 4,745,051) construction expression HuAFP (or its fragment or analog). This method generally comprises two steps. At first with gene to be expressed, for example rHuAFP or its fragment or analog (seeing below) are cloned on the plasmid transfer vector, be located at the downstream of bacilliform virus promoter, the flank of bacilliform virus promoter is the baculovirus DNA that comes from nonessential site, for example polyhedron gene. Then this plasmid is imported insect cell with ring-type wild type gene group DNA, make the generation homologous recombination. The filial generation of subsequently screening restructuring, for example, with order plaque analysis purification of Recombinant virus from non-recombinant type parental strain. In order to obtain the enough virus that is used for protein expression, usually must carry out virus amplification. Recombinant virus is carried out plaque purification, and confirm its dna structure with standard method well known in the art.
The cDNA fragment of from plasmid PI18, separating rHuAFP with EcoRI/BamHI, and utilize Geneclean hereinafter described to carry out purifying. Clone and the expression of HuAFP cDNA in baculoviral carried out with plasmid pVT-PlacZ. People AFP cDNA is cloned on the plasmid pVT-PlacZ (Fig. 7), be arranged in its 3 '-hold the frame of the melittin signal peptide sequence that produces into insect. To the modification of baculovirus vector pVT-PlacZ be by with oligonucleotides 5 '-GATCTAGAATTCGGATCCGGT-3 ' (sequence 21) and complementary fragment thereof substitute its MCS, comprise along 5 ' and EcoRI and the BamHI restriction site of 3 ' direction, described modification also comprises the number that reduces at melittin signal peptide cleavage site point and the non-AFP coding nucleotide between EcoRI endonuclease enzyme sequence insertion AFP cDNA site. Then described Insert Fragment is connected on the EcoRI and BamHI dna sequence dna of the pVT of modified-PlacZ carrier.
The recombinant baculovirus that contains the rHuAFP coded sequence according to the standard method preparation. By carrying out cotransfection with pVT-PlacZ transfer vector and wild-type baculovirus, and then carry out the purification of Recombinant baculoviral that the preparation of two-wheeled plaque purification contains the HuAFP coded sequence. With the Sf9 insect cell with 1 * 106The density of cell/ml is seeded in the serum-free Grace culture medium in the rotation flask that is contained in the 500ml volume, infects with recombinant baculovirus, and infection multiplicity is 5. Contain the supernatant of secreted rHuAFP by centrifugal results under 200xg, and remove cell. By the concentrated 10-20 of the culture medium that will contain rHuAFP with the ultrafiltration of YM30 Amicon film doubly, use the PBS dialysed overnight, then be filled on the ConA agglutinin post (Pharmacia). With the rHuAFP of the methyl α of 0.4M-D mannopyranose glycosides elution of bound, and by use the 20mM phosphate buffer, during the 0-100 % linear gradient of the 1M NaCl that pH8.0 prepares from the MonoQ post wash-out come purifying. Identify restructuring HuAFP with method well known in the art.
The inventor finds, the rHuAFP that is produced by baculoviral accounts for by the Sf9 insect cell and is secreted into 20% of total protein concentration in the serum free medium. PAGE finds that this AFP also is monomer by irreducibility alkalescence. Most of HuAFP that is produced by baculoviral is incorporated on the immobilization ConA. So, can effectively remove the scrambled proteins more than 90%, these albumen can not be combined on the agglutinin grain. With 270-310mM NaCl eluted protein from the Mono Q pearl, the rAFP preparation that is produced by baculoviral is carried out final purifying, obtain a kind of single peptide, its performance molecular weight is about 68KD. We can obtain the 1mg purifying protein at least from every liter of grown culture.
The molecular weight of the rHuAFP that is produced by baculoviral is similar to the molecular weight (Fig. 4 B) of natural human body molecule. Above-mentioned discovery, and the rHuAFP that produces of baculoviral be attached on the ConA post and the viewed rHuAFP that is produced by Escherichia coli is not joined on the ConA post and shows that the rHuAFP that is produced by baculoviral is glycosylated. But, expectation is lower than the degree of glycosylation of natural molecule by the degree of glycosylation of the rHuAFP (BrAFP) of baculoviral generation, lack the glycosylated ability of carrying out complexity because existing document is put down in writing the Sf9 cell of reorganized baculovirus infection, and this glycosylation is common in the high biogenic albumen that really changes. Single band on APAGE and SDS-PAGE (Fig. 4 A and 4B), and the purity of the rHuAFP that is produced by baculoviral that is shown in that FPLC and simple spike on the HPLC chromatogram among Fig. 4 C and the 4D confirmed to separate. The N-end sequencing has further confirmed the identity of purifying rHuAFP. The N-end sequence of described rHuAFP is: Asp-Leu-Gly-Phe-Met-Thr-Leu-His-Arg-Asn (sequence 22). Serum-free supernatant to the Sf9 cell that comes free recombinate shape virus infection carries out the Western engram analysis, detect one single and non-specific anti--immune response belt of HuAFP Ab, and in the Sf9 cell that infects or infected by wild-type virus, lack this band.
Test with means known in the art, to measure the BA by the baculoviral that HuAFP was produced. For example, 100 μ g/ml are to measure according to its ability that suppresses above-mentioned people AMLR by the immunosuppressive activity of the HuAFP of baculoviral generation. Shown in Fig. 5 and 6A, the rHuAFP that is produced by baculoviral can suppress to stimulate the id reaction Proliferation of lymphocytes effect that produces by self non-T cell in the time of 144 hours. And the human serum albumins that adds equivalent can not weaken the lymphopoiesis effect.
In order to confirm that rHuAFP is the substrate that determines the T cell of inhibition self propagation, stops the inhibitory action of the AMLR that is mediated by rHuAFP with commercially available mouse-anti people AFP monoclonal antibody (MAb). As shown in Figure 5, anti-HuAFP can thoroughly stop the rHuAFP that produced by 100 μ g/ml Escherichia coli and baculoviral to the inhibitory action of the id reaction T cell of propagation. Can not weaken the AMLR effect and add 100 μ g/ml HSA, and in the reaction culture, only have MAb to exist without any effect.
In addition, we have tested the BA that in the RPMI tissue culture medium (TCM) that only replenishes 2mg/ml Purification of Human albumin (ICN, Mississanga, ON) rHuAFP suppresses PBLC (PBL) propagation of being induced by mitogen. Shown in Table II (hereinafter) and Fig. 6 B, 100 μ g/ml rHuAFP can suppress the PBLs that ConA stimulates, and the albumin of same concentrations is inoperative.
According to standard method, with for example producing other rHuAFP[by above-mentioned baculovirus expression system such as the disclosed any method of this paper, rHuAFP (amino acid/11 (THr)-590 (Val); Sequence 5); Domain I (amino acid/11 (THr)-197 (Ser); Sequence 6); Domain II (amino acid/11 98 (Ser)-389 (Ser); Sequence 7); Domain III (amino acid 390 (Gln)-590 (Val); Sequence 8); Domain I+II (amino acid/11 (THr)-389 (Ser); Sequence 9); Domain II+III, (amino acid/11 98 (Ser)-590 (Val); Sequence 11)].
In one embodiment, carrier pVT-PlacZ/HuAFP (amino acid/11-590) is that the cDNA by the HuAFP that will encode inserts among the pVT-P10 and is built into, pVT-P10 is intermediate carrier [Richardson etc., (1992) " with the glycoprotein of baculovirus expression system design secretion " (the Engineering Glycoproteins for Secretion using the baculovirus expression System) that makes up pVT-PLacZ. See " method of baculoviral and generation recombinant protein " (Baculovirus and Recombinant Protein Production Processes), J.M.Viak, E.-J.Schlaeger and A.R.Bernard, Editiones Roche work, Basel, Switzerland, PP.67-73]. With BamHI digestion pVT-P10 carrier, then again with mung-bean nuclease (New England Biolabs, Mississ-auga, Ont.) together incubation. Then with EcoRI this carrier is done further hydrolysis in downstream, flush end BamHI site, be beneficial to the Direct Cloning of HuAFP cDNA. The rHuAFP cDNA of coded amino acid 1-590 obtains by pcr amplification, has adopted following Oligonucleolide primers during amplification: (5 '-AAAAAACTCGAGATACACTGCATAGAAATGAA-3 '; Sequence 23), its contain an Xhol site (5 '-AAAAAAGAATTCTTAAACTCCCAAAGCAGCACG-3 '; And contain the encode fragment of HuAFP as the plasmid p118 of template DNA sequence 24) and contain an EcoRI site. Described PCR reaction is undertaken by standard method, for example, is containing 34 μ LH2O, 10 μ L10 * reaction buffers, 20 μ LdNTP, 2 μ l dna profilings, 10 μ L 10pmol/ μ L5 ' primers, 10 μ L 10pmol/ μ L3 ' primers, 1 μ L glycerine carries out in the reactant mixture of 10 μ L dimethyl sulfoxide (DMSO)s (DMSO) and 1 μ LPfu polymerase. Annealing, extension and denaturation temperature also are according to standard conditions, for example carry out under 50 ℃, 72 ℃ and 94 ℃ respectively, carry out 30 circulations with Gene Amp PCR system 9600 (PerKing Elmer Cetus). With the DNA of Genaclean kit (Bio II Inc., LaJolla, CA) purifying from the PCR reaction. The rHuAFP fragment with Xhol digestion, is then processed with mung-bean nuclease first again. Then with EcoRI digestion HuAFP cDNA, be beneficial to its Direct Cloning to pVT-P10.
The rHuAFP cDNA that PCR is produced is connected on flush end 5 ' BamHI site and the 3 ' EcoRI site. By with Restriction Enzyme BamHI digestion from carrier pJVNheI[Vialard etc., (1990) " with the warm hemagglutinin of film of the synthetic measles virus of the new baculovirus vector with alpha-galactosidase gene " (Synthesis of the membrane fusion and hemagglutinin proteins of Measles (Virus, using a novel baculovirus vector containing the β-galactosidase gene), " Journal of Virology " be 64:37-50 (J.Virology)] in separate contain the beta galactose glycosides group in the polyadenylic acid site that comes from SV40 at its 3 ' end, be inserted into again compatible BgIII, produce final structure: pVT-PLacZ/HuAFP (containing amino acid/11-590). Then this structure is used for expressing rHuAFP (1-590).
Fragment and analog
The present invention includes the rHuAFP fragment of BA. Fragment with rHuAFP of BA has at least a in the following activity: (a) instruct the specificity with a kind of target cell to interact, for example, with express a kind of can be by the Cell binding of the acceptor of rHuAFP identification (for example, such as MCF-7 cancer cell or bone marrow cell film); (b) stop, weaken or suppress the growth (for example, be combined with cell surface receptor and produce a kind of antiproliferative signal) of tumour or id reaction immunocyte; Stimulate, improve, expansion or otherwise affect cell proliferation such as bone marrow cell (for example, on cell surface receptor in conjunction with a propagation or stimulus signal); Or stop or suppress or prevent the immunopathology antibody response. Can be with any standard well known in the art in conjunction with test determination rHuAFP fragment or analog in conjunction with can be by the ability of the acceptor of rHuAFP identification. Measure the BA of this fragment and analog with approach well known (such as the method that discloses in this article).
Generally, the rHuAFP fragment produces with above-mentioned expression of polypeptides and purification technique. For example, can transform suitable host bacteria cell by the part (such as above-mentioned cDNA) with the cDNA fragment that is combined in the coding HuAFP on the suitable expression vector and produce suitable rHuAFP fragment. In addition, can produce with the round pcr of standard above-mentioned fragment and being cloned on the expression vector (the same). Also can produce fragment (for example, with being disclosed in " solid-phase peptide synthetic " (Solid Phase Peptide Syn-thesis), second edition, the method in 1984, The Pierce Chemical Co., Rockford, I1) with chemical synthesis. Therefore, in case the rHuAFP fragment is expressed, can separate with various chromatographies well known in the art and/or immunization method. Before carrying out affinity chromatography, can contain the cell of rHuAFP and carry out the classification separation with the standard method cracking. Detect candidate rHuAFP fragment with method known to those skilled in the art and show the bioactive ability of alpha-fetoprotein (for example, with the disclosed method of this paper).
As indicated above, the rHuAFP fragment also can fusion protein form expression, produces in escherichia coli to merge form with maltose-binding protein.Adopt maltose-binding protein to merge and purification system (NewEngland Biolabs, Beverly MA), can be inserted in clone's human cDNA sequence the downstream of coding maltose-binding protein (malE) gene, and be arranged in the frame of this gene, then just can overexpression malE fusion rotein.When described human cDNA sequence go up to lack common restriction site, can with PCR method this cDNA segmental 5 ' and the 3 ' terminal restriction site that adapts to carrier of introducing so that the cDNA fragment is inserted in this carrier.After expressing fusion protein, can carry out purification by affinity chromatography.For example, can utilize the maltose-binding protein part and bonded this fusion rotein of ability purification of amylose that is fixed on the post of fusion rotein.
For convenience of protein purification, plasmid pMalE contains an Xa factor cracking site in the upstream that cDNA inserts the site of this carrier.Therefore, can maltose-binding protein be separated with people's recombinant cDNA gene outcome with the fusion rotein of the above-mentioned purification of Xa factor cracking subsequently.Can carry out further chromatography to this pyrolysis product so that from maltose-binding protein purification rHuAFP.In addition, can fusion protein form expression rHuAFP fragment, the fusion rotein of being produced contains the polyhistidyl fragment.Then, can separate this alpha-fetoprotein fusion rotein with a kind of combination of affinity column to fragment by poly-group ammonia, described affinity column has can be with high-affinity in conjunction with the segmental nickel part of polyhistidyl.Can be by changing this fusion rotein of pH eluting in the affinity column.By with this fusion rotein of special protease cracking, rHuAFP can be discharged from the polyhistidyl sequence that is present in resulting fusion rotein.
Can (for example recombinate HuAFP fragment expression product with determination of immunological methods, produced by above-mentioned any prokaryotic system), Western trace, immunoprecipitation analysis as the reconstitution cell extract, or immunofluorescence (for example, with disclosed methods such as Ausubel, " modern molecular biology scheme " (CurrentProtocols In Molecular Biology), Greene Publishing Associates and WileyInterscience (Jhon Wiley ﹠amp; Sons), New York, 1994).
If desired, can (see works such as Coligan with well-known method, " modern immunology scheme " (Current Protocols in Immunology) 1992, Greene Publishing Associates and Wiley-Interscience) gene outcome of purification or its fragment are used to prepare anti-people the recombinate polyclonal antibody or the monoclonal antibody of alpha-fetoprotein.In order to prepare monoclonal antibody, can use the recombiant protein immunized mice, the B cell of separation energy secretory antibody, and merge donor with the non-secretory myeloma cell and carry out immortalization.Screening is used to produce the hybridoma of recombinant human alpha-fetoprotein (or its fragment or analog) specific antibody then, and clones, to obtain to produce the even cell mass of monoclonal antibody.
As used in this article, " fragment " speech is when being used to represent the rHuAFP polypeptide, preferred its has 20 successive aminoacid at least, preferably have 50 successive aminoacid at least, most preferably have an appointment at least 200-400 or how successive aminoacid are more preferably arranged at least about 100 successive aminoacid.Can prepare the rHuAFP fragment with the method known to those skilled in the art, for example, the expression by albuminolysis cracking or recombinant peptide prepares, or is prepared by common albumen processing (for example, from newborn polypeptide is removed and biologic activity is irrelevant aminoacid).
Interested reorganization HuAFP fragment includes, but are not limited to domain I (amino acid/11 (Thr)-197 (Ser), referring to Fig. 1, sequence 6); Domain II (amino acid/11 98 (Ser)-389 (Ser), referring to Fig. 1, sequence 7), domain II I (aminoacid 390 (Gln)-590 (Val), referring to Fig. 1, sequence); Domain I+II (amino acid/11 (Thr)-389 (Ser); Referring to Fig. 1, sequence 9); Domain II+III (amino acid/11 98 (Ser)-590 (Val), referring to Fig. 1, sequence 10) and rHuAFP fragment I (aminoacid 266 (Met)-590 (Val), referring to Fig. 1, sequence 11).With the segmental activity of determination of experimental method, adopt routine techniques and analytical method, for example, the method that this paper is disclosed.
The present invention also comprises complete length rHuAFP or its segmental analog.Analog can because of aminoacid sequence difference do not influence the modification (for example, post translational modification) of its sequence or simultaneously because above two kinds former thereby be different from rHuAFP.The homology of analog of the present invention and all or part of aminoacid sequence of rHuAFP generally is at least 80%, and more preferably 85%, most preferably 90% or even 99%.Modify the interior adult outer chemical derivatization of body that (not changing its primary sequence usually) comprises polypeptide, for example, acetylation or carboxylated; This modification can be carried out during polypeptide synthesizes or processes, or after handling with independent modification enzyme.Analog also can be different from naturally occurring rHuAFP because of the change of primary sequence, for example, similar characteristics aminoacid is arranged (for example with a kind of aminoacid replacement another kind, use the valine substituted glycinic acid, replace lysine etc. with arginine) or do not lose displacement, disappearance or the insertion of one or several non-conserved amino acid of the biologic activity of this polypeptide.[for example handle and carry out random mutagenesis or with disclosed method (" molecular cloning: experiment guide " (Molecular Cloning:A Laboratory Manual) such as Sambrook comprising natural and inductive hereditary variant by radiation or ethyl sulfonic acid methyl ester, 2nd ed.Cold Spring Harbor Press, 1989, or Ausubel etc., the same)] carry out site-specific mutagenesis, also comprise the cyclisation peptide molecule and contain the L-aminoacid analog of residue in addition, for example, that D-aminoacid or non-natural exist or synthesizing amino acid, for example, β or γ aminoacid, or the L-aminoacid that has a non-natural side chain (for example, referring to Noren etc., " science " be 244:182 (Science), and 1989).For example, Ellman etc. have disclosed (seeing " science " (Science) 255:197,1992) locus specificity that alpha-non-natural amino acid mixes proteinic albumen main chain have been mixed method.Also comprise the polypeptide of chemosynthesis or have modification peptide bond (for example, at United States Patent (USP) 4,897,445 and United States Patent (USP) 5,059, the non-peptide bond disclosed in 653) or modify the peptide of side chain, to obtain ideal medicament characteristic as herein described.Adopt conventional method, for example the disclosed method of this paper is identified useful mutant and analog.
To recombinate HuAFP as immunosuppressant
Analyze in the body or external immunoregulatory activity with any standard method, to measure the immunosuppressive action of rHuAFP (or its fragment or analog).As mentioned below, this area provides some and has been used for checking in the body rHuAFP (or its fragment or analog) to autoimmune disease, for example, and the animal system of the immunosuppressant feature of non-obese diabetes (NOD) mice.In addition, also have the multiple vitro system that can be used for checking the immunosuppressant feature of rHuAFP, for example, a kind of such analyzed in vitro method can be determined in the AMLR (AMLR) inhibitory action to the inductive T cell proliferation of autoantigen.
Following embodiment confirms that nonglycosylated rHuAFP and rHuAFP fragment energy suppressor T cell effect are in the automatic propagation of autoantigen.The usefulness of these embodiment is intended to explanation, rather than restriction the present invention.
Embodiment
Material and method
Gel electrophoresis, immunoblotting and purification
Measure purity and the feature of rHuAFP by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and non-degeneration alkalescence PAGE (APAGE) with standard method.Subsequently gel is carried out following analysis: or by coomassie brilliant blue staining, or (Millipore, Mississauga carry out immunoblotting assay on ON) by electrophoresis isolating polypeptide to be transferred to the Immobilon film.Identify the anti-natural HuAFP polyclonal antibody complex of the non-specific rabbit of reorganization HuAFP with the goat anti-rabbit igg that alkali phosphatase is puted together, and according to manufacturer's description, (BioRad Laboratories Mississange ON) detects immune response belt with the BCIP/NBT chromophoric solution.
Carry out column chromatography by standard method.
The segmental polymerase chain reaction of rHuAFP (PCR)
With the segmental plasmid structure of technical field of molecular biology technical staff known round pcr preparation coding human a-fetoprotein, use be designed to increase human a-fetoprotein the gene specific part oligonucleotide primers [for example, referring to " round pcr " (PCR Technology), H.A.Erlich, work, StochtonPress, New York, 1989; " PCR scheme: methods and applications guide " (PCR Protocols:AGuide to Methods and Applications), M.A.Innis, David H.Gelfand, JohnJ.Sninsky and Thomas J.White work, Academic Press, Inc., New York, 1990, with Ausubel etc., the same].
Prepare following 6 kinds of rHuAFP fragments, measure its biologic activity (for example, with the disclosed method of this paper):
Domain I amino acid/11 (Thr)-197 (Ser), (Fig. 1, sequence 6)
Domain II amino acid/11 98 (Ser)-389 (Ser), (Fig. 1, sequence 7)
Domain II I aminoacid 390 (Gln)-590 (Val), (Fig. 1, sequence 8)
Domain I+II amino acid/11 (THr)-389 (Ser), (Fig. 1, sequence 9)
Domain II+III amino acid/11 98 (Ser)-590 (Val), (Fig. 1, sequence 10)
RHuAFP fragment I aminoacid 266 (Met)-590 (Val), (Fig. 1, sequence 11)
Aminoacid sequence is human a-fetoprotein (1 (Thr)-590 (Val) shown in the basis; Among Fig. 1 sequence 5) sequence infer.The fragment that is named as the rHuAFP of domain I, domain II, domain II I, domain I+II, domain II+III and rHuAFP fragment I is synthetic with the PCR reaction condition of standard, contains 34 μ L H in 100 μ L reactant mixtures 2O, 10 μ L, 10 * reaction buffer, 20 μ L 1mMdNTP, 2 μ L dna profilings (being cloned in the HuAFP on the pI18), an amount of 5 ' and 3 ' oligonucleotide primers (10 μ L 10pmol/ μ L5 ' primers, 10 μ L 10pmol/ μ L3 ' primers), 1 μ L glycerol, 10 μ L dimethyl sulfoxide (DMSO) and 1 μ L Pfu polymerase (Stratagene, LaJolla, CA).The primer that is used for pcr amplification is:
Domain I25 5 '-AAAAAAGGTACCACACTGCATAGAAATGAA-3 ' (sequence: 14)
Domain I3 5 '-AAAAAAGGATCCTTAGCTTTCTCTTAATTCTTT-3 ' (sequence: 15)
Domain II 55 '-AAAAAAATCGATATGAGCTTGTTAAATCAACAT-3 ' (sequence: 16)
Domain II 35 '-AAAAAAGGATCCTTAGCTCTCCTGGATGTATTT-3 ' (sequence: 16)
Domain II I5 5 '-AAAAAAATCGATATGCAAGCATTGGCAAAGCGA-3 ' (sequence: 16)
Domain II I3 5 '-AAAAAAGGATCCTTAAACTCCCAAAGCAGCACG-3 ' (sequence: 17)
5 ' rHuAFP fragment I 5 '-AAAAAAATCGATATGTCCTACATATGTTCTCAA-3 ' (sequence: 18)
Therefore, primer can be respectively applied for the cDNA sequence of the domain I, domain II, domain II I, rHuAFP fragment I, domain I+II and the domain II+III that extract rHuAFP to DomI25 and DomI3, DomII5 and DomII3, DomIII5 and DomIII3,5 ' rHuAFP fragment I and DomIII3, DomI25 and DomII3 and DomII5 and DomIII3.Annealing, extension and denaturation temperature are respectively 50 ℃, 72 ℃ and 94 ℃, carry out 30 circulations.Use the standard method purified pcr product.The PCR product of purification coding structure territory I and domain I+II is separately with KpnI and BamHI digestion, and is cloned into respectively on the pTrp4 that KpnI/BamHI handled.The purified pcr product of coding structure territory II, domain II I, domain II+III and rHuAFP fragment I is respectively with Bsp106I and BamHI digestion, and is cloned into respectively on the pTrp4 that Bsp106I/BmHI handled.Subsequently every germplasm kernel structure is changed in the competence Bacillus coli cells.Because expression product starts from by translation initiation signal methionine amino acid sequence coded, estimates that this signal will be removed, or can influence the biological activity of final expression product in no instance.
AMLR (AMLR)
Extract human peripheral blood mononuclear cell (PBMC), its fractionated is become non-T cell group and AMLR with standard method.By allowing 1.5 * 10 8PMBC from commercially available Ig-anti--Ig affinity column (BiotekLaboratories) goes up by coming separation effect T cell, subsequently with 2 * 10 5The effector lymphocyte with from self of single donor 137The non-T irritation cell of Cs-radiating (2500 rad) is cultivated together.Used culture medium is for having replenished 20mM HEPES (Gibco), 5 * 10 -5M2-mercaptoethanol (BDH, Montreal, QC), the RPMI-1640 of 4mML-glutamine (Gibco), 100 μ/ml penicillin (Gibco) and 100 μ g/ml sulphuric acid chain enzymes, when being used for AMLR, add again 10% effector T cell donor from body Freshman serum.When beginning to cultivate, add various concentration purification rHuAFP, human serum albumin (HSA), anti-HuAFP monoclonal antibody Clone#164 (final concentration in culture is 125 μ g/ml) (Leinco Technologies St.Louis, MO).With the AMLR culture under 37 ℃ in 95 air and 5% CO 2The middle cultivation 4-7 days.With indicated interval, by with 1 μ Ci 3(specific activity is 56-80Ci/mmole to the H-thymidine, ICN) carries out pulse in 6 hours, and it is synthetic to measure DNA.(Skatron, Sterling VA) go up the collection culture, and measure on a Packard 2500 TR liquid scintillation counters at a various product catcher 3H-TdR mixes.Given result is the standard error of average cpm ± 3 or 4 meansigma methodss that repeat to cultivate.
Peripheral blood lymphocyte (PBL) is measured
With 1: 1 ratio with the blood of PBS dilution heparinization from the normal human, by Ficoll-Hypaque (Sigma, St.louis, MO) enterprising line density centrifugal from Red blood corpuscle separation of human peripheral blood lymphocyte (PBL).At least with PBS it is washed 3 times, and by trypan blue repelling attack identification of cell activity.Cultivate people PBL (2.5 * 10 with standard method 5Cell).The SEM that repeats to cultivate with average Cpm thymidine incorporation ± 3 times comes ecbatic.
The result
Express and purification
Decomposition the single band of blue painted APAGE of the coomassie shell shown in Figure 1A-1B and SDS-PAGE confirmed the purity of isolating rHuAFP at expression in escherichia coli.Coming from the protein fractions that the general Q-Sepharose chromatography of colibacillary soluble and monomeric rHuAFP eluting contains HuAFP obtains.By FPLC Mono-Q anion exchange, from every liter of bacterial cultures, return so to the pure rHuAFP of about 1mg with 220-230mM NaCl, it is single even peak, its migration amount at SDS-PAGE is about 65KD (1B), on SDS-PAGE, the natural HuAFP's of molecular weight ratio of reorganization HuAFP is low, because prokaryotic expression system lacks the required enzymatic mechanism of protein glycosylation.On FPLC and HPLC, pure rHuAFP sample is carried out chromatography again, obtain the simple spike shown in Fig. 1 C and the 1D, confirmed the purity of this rHuAFP.In addition, N-end sequencing data is consistent with the-terminal amino acid sequence of the rHuAFP of expection.
In addition, cultivate the escherichia coli of the expression plasmid that contains the rHuAFP that encodes as stated above.The feature of showing purification rHuAFP fragment I among Fig. 2 (swimming lane D).The-terminal amino acid sequence analysis shows that the aminoacid sequence that rHuAFP fragment I has is: Ser 267-Tyr-Ile-Cys-Ser-Gln-Gln-Asp-Thr 275(sequence 13), the-terminal amino acid sequence of the rHuAFP fragment I of this sequence and expection (referring to Fig. 1, sequence 11) unanimity, wherein, the methionine of beginning excises at cell interior.
The inhibition of AMLR (AMLR)
Measure the immunosuppressive activity of rHuAFP according to its ability that suppresses people's AMLR (AMLR).Shown in Fig. 8 A,, measure the inhibition of rHuAFP to the id reaction lymphopoiesis effect that stimulates by self non-T cell by in 4-7 days time, measuring self propagation.Shown in Fig. 8 B, confirm by the resulting result of dose response studies who carries out at T cell self propagation place, peak, when cultivating beginning, add rHuAFP and can the mode relevant suppress AMLR with dosage.In addition, parallel activity research confirms that rHuAFP is not because the non-specific cell toxic action to people's id reaction T cell inhibiting activity.
In order further to confirm that rHuAFP is the inhibiting inhibitor that determine self proliferative T cell, the inhibitory action of the AMLR that mediates with commercially available mouse-anti people AFP monoclonal antibody (MAb) prevention rHuAFP.As shown in Figure 5, anti-HuAFP MAb can stop the id reaction T cell inhibiting effect of 100 μ g/ml to propagation fully.Add 100 μ g/ml HSA and can not destroy the AMLR effect, in the reaction culture, MAb is only arranged also without any effect.
The recombinant polypeptide that produces in prokaryotic expression system has the danger of being polluted by host cell lipopolysaccharide (LPS) when extracting from cell.Confirmed already, the biological activity that a spot of LPS can the antagonism cytokine, thus destroy the immunoreation of macrophage.Therefore, endotoxin is to measure like this to the influence of various rHuAFP preparations: use from Detoxi-gel (pierce) and upward carry out the AMLR experiment by having eliminated endotoxic recombiant protein and untreated rHuAFP.More than experiment shows that two kinds of preparations have the immunosuppressive activity of par.
Shown in Fig. 8 A and 8B, the result of this research also shows, rHuAFP can suppress the propagation of id reaction T cell with the effectiveness identical with glycosylation rHuAFP, T cell to self propagation in vitro reactions produces inhibitory action, and inhibitory action is clearly arranged when the concentration of rHuAFP is in 5 μ g/ml-100 μ g/ml scopes.In addition, as table 1 and shown in Figure 3, rHuAFP fragment I can suppress the lymphocytic multiplication effect of id reaction by self non-T cell stimulation in the time of 144 hours.And as shown in Figure 3, domain I and III also can suppress AMLR.
Table I
Reaction scheme Thymidine incorporation (CPM)
The T cell 7118±964
AMLR 83103±6480
AMLR+rHuAFP fragment I (100 μ g/ml) 29692±2963
The inhibition of peripheral blood lymphocyte reaction (PBL)
The immunosuppressive activity of the rHuAFP (as mentioned below) that has also checked 100 μ g/ml rHuAFP fragment I and produced by escherichia coli and baculovirus is checked the ability that suppresses human peripheral lymphocyte reaction (PBL).As shown in Table II, rHuAFP that is produced by escherichia coli and baculovirus and fragment I (producing as stated above) are proved the multiplication effect that can suppress the human peripheral lymphocyte that ConA stimulates.
Table II
3H-thymidine incorporation (CPM ± SE)
No albumen 102,353±5,566 91,502±4,333 99,700±4,464
100 μ g/ml human albumins 89,860±5,800 82,924±11,085 94,123±1,633
100 μ g/ml escherichia coli rHuAFP 33,641±3,893 - -
100 μ g/ml baculovirus rHuAFP - 31,331±6,303 -
100 μ g/ml fragment I - - 39,019±161
Autoimmune disease
As indicated above, the characteristics of autoimmune disease be forfeiture to the toleration of autoantigen, cause reacting with the tissue antigen of self such as the immune system cell of T or B cell (or both).Autoimmune disease relates to all tracts, but some organ is than other organs susceptible to more.The example that being subjected to exempt from the tissue that symptom influences from experiencing has: the white matter of patients with multiple sclerosis brain and spinal cord; The lining in rheumatoid arthritis patients joint; β island cell with excreting insulin on insulin-dependent diabetics's the pancreas.The kidney and other organ that are connected or destroy Patients with SLE between the nerve that the autoimmune condition of disease of other form destroys the myasthenia gravis patient and the muscle.The example of other autoimmune disease includes, but are not limited to Addison ' s disease, Crohn disease, Grrave ' s disease, psoriasis, scleroderma and ulcerative colitis.
This area provide the multiple transgenic that is used for the test of cure human body diseases relevant and not genetically modified laboratory animal system with autoimmune disease [for example, referring to Panl, W.E., " basic immunology " Fundamental Immunology), 2nd ed, Raven Press, New York, 1989; With Kandel etc., " neuroscience method " (Principles of Neural Science), 3rd ed., Appleton and Lange, Novwalk, CT, 1991; And " current immunology scheme " (Current Protocols In Immunology), Coligan, J.E., Kruisbeek, A.M., Margulies, D.H.Sherach E.M. and Strober work, Green Publishing Associates (John Wiley ﹠amp; Sons).New York 1992]。Above-mentioned experimental result has confirmed the immunosuppressive activity of non-glycosylated rHuAFP, has reason to think that taking this rHuAFP that produces in prokaryotic system (or its fragment or analog) can treat other autoimmune disease.Therefore, the invention provides the purposes that rHuAFP (or its fragment or analog) is used for the treatment of (i.e. prevention, or inhibition, or improvement, or promotion alleviation) all autoimmune diseases.
It below is the example that can be used for measuring the animal system of recombinant human alpha-fetoprotein or its immunocyte antiproliferative fragment or the analog effectiveness aspect the treatment autoimmune disease.These examples are to be used to illustrate of the present invention, rather than will limit the present invention.
Multiple sclerosis
Multiple sclerosis (MS) is the dispersion demyelinating disease partly of a kind of central nervous system's of relating to white matter.In MS, myelin basic protein and proteolipid protein(PLP) are the main targets that relates to the lymphocytic autoimmune response of T in other immune system composition.The forfeiture of neurocyte myelin (demyelination) can cause neurological's symptom, and finally causes stupor or paralysis.
Experiment autoimmune encephalomyelitis (EAE) is the main models that this area is used to check and measure the effect of the therapeutic agent for the treatment of MS.EAE is the inflammatory autoimmune demyelinating disease of bringing out in laboratory animal by to central nervous system's immunity.When the left agent of giving animal (as mice, rat, intestinal Mus, rabbit, monkey etc.) injection such as Freund's complete adjuvant adds myelin basic protein or proteolipid protein(PLP), can bring out EAE, similar MS[is for example on pathology for it, referring to Alvord etc., " experiment autoimmune encephalomyelitis-a kind of useful model that is used for multiple sclerosis " (Experimental Allergie Enceph-alomyelitis-A Useful Model for Multiple Sclerosis), Liss, New York, 1984; Swanberg, " Enzymology method " be 162:413 (Meth.Enzymol.), and 1988; With McCarron etc.) " Journal of Immunology " J.Immunol.), 147:3296,1991].
In order to check rHuAFP or its fragment or analog, on suitable laboratory animal, bring out EAE, for example, on mice or rabbit, bring out EAE with means known in the art.In order to estimate the immunosuppressive effect of certain chemical compound to EAE, i.e. its prevention or improve the ability of EAE is used such as the standard method of injecting in intravenous or the goldbeater's skin with the described chemical compound of suitable dosage administration every day.Generally, administration is before bringing out EAE and/or occurs beginning after the EAE clinical symptoms.Contrast is to the placebo of thing acceptance such as the human serum albumin, to be similar to the mode administration placebo of administration rHuAFP or correlation molecule.Detect of the influence of test molecule according to any standard method to EAE.For example, monitor weight minimizing and the muscle paralysis that EAE brings out animal every day.If desired, brain and myeloid tissue [are for example carried out histology, with any normal structure chemistry or immunohistochemical method, for example referring to Ausubel etc., " modern molecular biology scheme " (Current Protocols In Molecular Biology), Greene PublishingAssociates (John Wiley ﹠amp; Son), New York, 1994; Bancroft and Stevens, " theory and practice of tissue chemical technology " (Theory and Practice of Histochemical Techniques), Churchill Livingstone, 1982], and tissue sample carried out microscopy, seek the evidence of EAE, for example the evidence of perivascular cell sepage.Animal of handling and the comparative study between the control animal are used for the confirmed test molecule in prevention or improve relative effectivenes aspect the EAE.The molecule that can prevent or improve the symptom of (alleviate, or suppress, or alleviate, or weaken) EAE is regarded as can be used for the present invention.
Rheumatoid arthritis
Rheumatoid arthritis (RA) is a kind of chronic disease, and this disease can make the synovial membrane inflammation in multiple joint, causes the damage to cartilage and bone.RA is with people's lymph antigen (HLA)-DR4 is relevant, and is regarded as a kind of autoimmune disease of the T of relating to cell, and for example, referring to Sewell etc., " lancet " be 341:283 (Lancet), and 1993.RA is because of due to the interaction of synovial cell and various cytokine (and soluble product), and described cytokine is the synovial membrane lining that infiltrates the joint from blood circulation.A series of biology of the incident that is taken place finally causes invading and corrodes the collagen in joint and the detrimental effect of cartilage matrix.
Several A R animal model, for example the MRL-lpr/lpr mice is well-known in the art, these models can produce the arthritic symptom (for example, the same referring to " basic immunology " (Fundamental Immunology)) of similar human diseases.Can on suitable animal, bring out autoimmune collagen arthritis (ACA) and adjuvant arthritis (AA) (adjuvant arthritis) with standard method in addition.
In order to measure the immunosuppressant of rHuAFP or its fragment or analog to RA, promptly this chemical compound prevents or improves the ability of RA, take the test molecule for the MRL-lpr/lpr mice with standard method, described method such as intravenous or peritoneal injection are with proper dosage administration every day.Generally, administration is before the RA outbreak and/or occurs beginning after the RA clinical symptoms.Control animals receive placebo, for example, the human serum albumin, with administration rHuAFP or the similar method administration of correlation molecule placebo.With of the influence of standard method monitoring test molecule to RA.For example, by the analysis result of monitoring every day to the cell component of synovial joints.If desired, can to synovial joints carry out histology (for example, adopt the histochemistry or the immunohistochemical method of any standard, for example,, the same referring to Ausubel etc.; Bancroft and Stevens, the same), and tissue sample carried out microscopic examination, to seek the evidence of RA, for example, the erosive evidence of collagen and cartilage matrix in the joint.Animal of handling and the comparative study between the control animal are used to the determination test molecule in prevention or improve relative effectivenes aspect the RA.The test molecule that can prevent or improve (alleviate, or suppress, or alleviate, or promote to weaken) RA symptom is regarded as can be used for the present invention.
Myasthenia gravis
Myasthenia gravis (MG) is that a kind of neuromuscular transmits disease, this sick autoantibody that can produce the acetylcholinergic receptor of anti-neuromuscular junction.Antibody is encroached on described joint, causes weakness and paralysis.Women's sickness rate is 2 times of male, morbidity about 30 years old usually.The main feature of this disease is a myasthenia.Clinical symptoms comprises that blepharoptosis and double vision resemble.MG is relevant with hyperthyroidism.
Studied the experiment autoimmune MG (EAMG) that comprises rabbit, monkey, Lewis rat and the mice selfing product multiple animal in tying up to already, the symptom of EAMG is similar to the basic feature of human diseases.[for example, the same] referring to " neuroscience method " (Principles ofNeutral Science).Inject acetylcholinergic receptor one time with adjuvant, for example, the receptor of purification from the electrical equipment pipe of eel (Torpedo californica) can cause acute unable symptom in 8-12 days, and chronic unable symptom appears in the back about 30 days then.Reaction to the eel receptor is a T cell decision type.C57BL/6 strain (H-2 B) be the high effect body of Torpedo receptor, and height susceptible EAMG.
For checking R huAFP or its fragment or analog, with method well known in the art such as C57BL/6 strain (H-2 B) bring out EAMG on the suitable laboratory animal of mice.In order to check the immunosuppressive effect of certain chemical compound to EAMG, promptly prevent or improve the ability of EAMG, with this chemical compound of standard method administration, for example, with the form of intravenous or peritoneal injection with administration every day of suitable dosage.Generally, administration is before bringing out EAMG and/or occurs beginning after the EAMG clinical symptoms.Control animals receive placebo, as the human serum albumin, with administration rHuAFP or the similar mode administration of correlation molecule placebo.With of the effect of standard method monitoring test molecule to EAMG.For example, carry out nerve stimulation analysis (for example, with the method that Pachner etc. discloses, " neurological's record event " be 11:48 (Ann.Neurol.), 1982) in the EMG analysis of the animal that can bring out EAMG.If desired, it is (for example, with the histochemistry or the immunohistochemical method of any standard, for example, referring to Ausubel etc., the same to carry out histological inspection to tissue sample; Bancroft and Stevens, the same), and tissue sample is carried out microscope check, to find the evidence of EAMG, for example, mononuclear cell infiltration and/or autoantibody are positioned the evidence of the acetylcholinergic receptor of neuromuscular junction.Animal of handling and the comparative study between the control animal are used to the determination test molecule in prevention or improve relative effectivenes aspect the EAMG.The molecule that can prevent or improve (alleviate, or suppress, or alleviate, or promote to weaken) EAMG symptom is regarded as can be used for the present invention.
Insulin-dependent diabetes
Diabetes are a kind of glucose metabolism diseases.Insulin-dependent diabetes (IDDM) is known as type i diabetes again, it is a kind of autoimmune disease, it is characterized in that being accompanied by the immunoreation that causes by multiple self peptide, cause hyperglycemia and other pathology symptom by the destruction of the pancreatic beta cell on the cell-mediated Lang Shi island of T.IDDM patient relies on exogenous insulin to keep normal glucose metabolism.Can be before hyperglycemia outbreak according to glucagon, island cell, glutamic acid carboxylase and other oneself protein occur unusually defining IDDM danger takes place human body (for example, referring to, Baekkeskov etc., " Journal of Clinical Investigation " be 79:926 (J.Clin.lnvest.), and 1987; Dean etc., " diabetology " be 29:339 (Diabetologia), and 1986; Rossini etc., " immunity is commented academic year " be 3:289 (Annu.Rev.Immunol.), and 1985; Srikanta etc., " New England Journal of Medicine " be 308:322 (N.Engl.J.Med.), and 1983).The type of general autoantibody can indicate final disease progression and/or the danger of morbidity (for example, referring to Keller etc., " lancet " be 341:927 (Lancet), 1993).
Can comprise Bio-Breeding (BB) rat and non-obese diabetes (NOD) mice by the spontaneous example that is similar to the animal model of human body diseases.Diabetes also can with streptozotocin (streptozotocin) by experiment method bring out.
BioBreeding rat can the spontaneous disease that is similar to IDDM, with insulitis (mononuclear cell infiltration islets of langerhans) and resist self cell and insulin (for example, referring to Baekkeskov etc., " Journal of Clinical Investigation " be 79:926 (J.Clin.Invest.), 1987; Rossini etc., the same; Nakhooda etc.) " diabetes " (Diabetes) 26:100,1977; Dean etc., " clinical experiment immunology " be 69:308 (Clin.Exp.Immunol.), and 1987).
Insulitis takes place in NOD mice usually when age in 5-8 week, 70% female, 40% male trouble diabetes that become were arranged when 7 monthly ages.The T cell transfer of diabetic mice can be brought out diabetes (for example, referring to Bendelac etc., " The Journal of Experimental Medicine " be 166:823 (J.Exp.Med.), 1987) to the inherent 2-3 of nascent non-diabetic NOD mice body in week.The NOD mice is dead in the month at 1-2 usually after diabetes take place, unless accept insulinize.
Can chemically bring out diabetes by multiple low dose injection streptozotocin, streptozotocin is toxic to pancreatic beta cell, and it can cause serious insulitis and diabetes (for example, referring to Kikutani etc., " immunology progress " be 51:285 (Adv.Immunol.), and 1992).
Therefore, this area provides the animal model of multiple anthropomorphic dummy IDDM, these animal models can be used to check and test the method that is used to prevent or improve diabetes, these methods to relate to rHuAFP (or its fragment or analog).
In order to measure rHuAFP or its fragment or analog immunosuppressive effect to the morbidity of diabetic mice, the i.e. ability of this compounds for treating or prevention insulitis and diabetes is used such as the standard method of intravenous or peritoneal injection and is given the suitable suitable test compound of experimental animal administration every day with suitable dosage.Generally, administration is to carry out before insulitis and the diabetes outbreak and/or after the diabetes clinical symptoms occurring.Control animals receive placebo, as the human albumin, with administration rHuAFP or the similar mode administration of correlation molecule placebo.With of the influence of standard method monitoring test molecule to insulitis and diabetes.For example, monitor weight loss, ketoboidies formation and blood sugar concentration every day.If desired, it is (for example, with the histochemistry or the immuno-chemical method of any standard, for example, referring to Ausubel etc., the same to carry out histological examination to islet cells; Bancroft and Stevens, the same), and tissue sample carried out microscope inspection, to seek the evidence of insulitis and β primary cellular defect.Animal of handling and the comparative study between the control animal can be used for the determination test molecule in prevention or improve relative effect aspect the diabetic symptom.Can prevent or improve (alleviate, or suppress, or alleviate, or promote to weaken) diabetes,, be regarded as can be used for the present invention as the molecule of IDDM symptom.
Systemic lupus erythematosus (sle)
Systemic lupus erythematosus (sle) (SLE) is a kind of serious systemic autoimmune disease.The patient of this disease has 90% to be the young woman approximately.This significant women's advantage does not exist before adolescence He after the menopause.This disease starts from the initial stage of growing up usually, and distinctive erythra appears in cheekbone and forehead the patient during morbidity.Alopecia is common, serious kidney damage, arthritis also can occur, the inflammation of hydrops and pulmonary's lining around heart.Having also can inflammation near the patient's of half cerebrovascular, causes paralysis and faints from fear.The effect of this disease is the same with other autoimmune disease, can produce fluctuation: quiescent period in good health over a long time may stop suddenly and indescribable morbidity again.Known have a large amount of different autoantibodys in SLE, for example, and the autoantibody of anti-DNA, RNA and histone (for example,, the same) referring to " basic immunology " (Fundamental Immunolgy).
The animal model of some kinds of human SLE is known in the art, and for example, the selfing mouse species comprises NIB mice and F thereof 1Hybrid, MRL mice and BXSB mouse are (for example, referring to Bielschowsky etc., " institute of pharmaceutical college of Otago university periodical " (Proc.Univ.Otago Med.Sch.) 37:9,1959; Braverman etc., " Dermatology research magazine " be 50:483 (J.Invest.Derm.), and 1968; Howie etc., " immunology progress " be 9:215 (Adv.Immunol.), and 1968; " the genetic control control of autoimmune disease " (Genetic Contral of Autoimmune Diease), Rose, M.Bigazzi, P.E., and Warner, N.L. work, Elsevier, Amsterdam, 1979; " modern immunology scheme " (Current Protocols In Immunology), the same).For example, NZB * NZW F 1Mice is a kind of fabulous human SLE model, and female mice can produce a large amount of anti-two strandss and anti-single stranded DNA autoantibody, other antinuclear antibody and trouble nephropathy; Dead (for example, referring to Theofilopoulos etc., " immunology progress " Adv.Immunol.) 37:269 appearred usually, 1985) in the time of about 8 months.
In order to measure rHuAFP or its fragment or analog immunosuppressive action to SLE, i.e. chemical compound rHuAFP prevention or improve the ability of SLE, use give every day with suitable dosage such as the standard method of intravenous injection or peritoneal injection suitable for NZB * NZW F 1The animals administer test compound of mice.Generally, administration is before the SLE outbreak and/or occurs beginning after the SLE clinical symptoms.Control animals receive placebo, for example, the human albumin, with administration rHuAFP or the similar mode administration of correlation molecule placebo.Monitor of the influence of described test compound with standard method to SLE.For example, can monitor analysis such as the autoantibody of anti-DNA antibody.If desired, it is (for example, with any normal structure chemistry or immunohistochemical method, for example, referring to Ausubel etc., the same to carry out histological examination to nephridial tissue; Bancroft and Stevens, the same), and tissue sample carried out microscope inspection, to seek the evidence of SLE, for example, the evidence of lupus nephritis.Animal of handling and the comparative study between the control animal can be used for the determination test chemical compound in prevention or improve relative effect aspect the SLE.The molecule that can prevent or improve (weaken, or suppress, or alleviate, or promote to alleviate) SLE symptom is regarded as can be used for the present invention.
The treatment administration
As mentioned above, the reorganization alpha-fetoprotein, the propagation that can effectively suppress the autoimmune cell as rHuAFP (or its fragment or analog), therefore, can be used to prevention or improve autoimmune disease, include, but are not limited to multiple sclerosis, rheumatoid arthritis, diabetes, systemic lupus erythematosus (sle) and myasthenia gravis.Therefore, can prepare recombinant human alpha-fetoprotein (or its fragment or analog) with known method, with the preparation can be medicinal compositions.
Preferably give this sick patient's administration reorganization alpha-fetoprotein, as rHuAFP (or its fragment or analog) with the amount that can effectively prevent or improve the autoimmune disease symptom.Generally, be advisable with the dosage of 0.1ng/kg body weight-10g/kg body weight.If desired, mode that can administration every day is carried out.Because there be not the known harmful side effect relevant with recombinant human alpha-fetoprotein, therefore, it is believed that can be safely with the higher dosage administration.For example, can treat human patients with the rHuAFP that is contained in the treatment effective dose in the acceptable carrier on the physiology (or its fragment or analog).Suitable carriers and prescription thereof are disclosed in the Remington ' s pharmacy (Pharmaceutical Sciences) by E.W.Martin.The dosage of rHuAFP because of administering mode, patient's age and body weight, ill type with easily susceptible or just different at ill patient's build.For example, that preferred administering mode comprises is subcutaneous, intravenous, intramuscular or intradermal injection, and these methods can continue to keep the intravital levels of drugs of patient.In other preferred modes, can give patient's administration rHuAFP by the mode of injection or implantation slow releasing preparation, for example, described rHuAFP is slow dissociated polymerization or crystal form; Before this class continues medication, can carry out initial administration with more normal mode (as above-mentioned mode).In addition, can be with inculcating pump (for example, the external or implantable pump of inculcating) administration rHuAFP, so that accurate control drug release speed, or be used to promote insulin inhaled mode that rHuAFP is implanted nasal meatus to be similar to.As a kind of alternative through Nasal Mucosa Absorption, can be with aerosol precipitation or the solution form input pulmonary of rHuAFP with powder.
In addition, method of the present invention can also adopt the combined therapy form, wherein, rHuAFP is with such as the therapeutic agent of common or special tolerance agent simultaneously or take successively, for example, described therapeutic agent is antiidiotype agent (as monoclonal antibody) or treatment vaccine or oral agents (as insulin, collagen or myelin basic protein) or cytokine (as I1-15) or interferon (alpha-interferon) or immunosuppressant.Preferably with effective dose administration immunosuppressant, the dosage when this dosage is lower than this immunosuppressant of independent use.Preferred immunosuppressant is cyclosporin, FK-506, steroid, azathioprine or 15-deoxyspergualin.
Treatment generally starts from diagnosis or suspects when suffering from autoimmune disease, and general every day repetitive therapy.Administration rHuAFP can prevent or prevent the generation (or development or deterioration) of autoimmune disease before morbidity.If desired, can test to the effect of treatment or prevention scheme with the method for monitoring or diagnosis patient autoimmune disease.
Recombined human AFP is used for the treatment of or cancer diagnosis
Cytotoxic agent
By total length rHuAFP or its fragment or analog being puted together the hybrid cell toxin for preparing rHuAFP with any amount of known toxicity agent with routine techniques.These toxin can be used for suppressing the generation (as mentioned below) of tumor.Useful cytotoxin just has significant cytotoxicity preferably only in being present in cell the time, and is excluded basically outside the specific cells that lacks the target structure territory.As mentioned above, the peptide toxin satisfies above standard and can easily be attached on the hybrid molecule.Also can use blended cytotoxin (promptly by two or more all or part of cytotoxin of forming of toxin) if desired.To illustrate in greater detail several useful toxin below.
The lps molecule that is used for the inventive method is preferably such as the toxin of peptide toxin, and this toxin just has significant cytotoxicity only in coming across cell the time.Certainly, in this case, described lps molecule must can enter the cell that has the target receptor.This ability depends on the character of molecule and the character of cell receptor.For example, can make the cell receptor that absorbs part naturally as if can provide the means that enter the cell that has described receptor for the molecule that includes toxin.As mentioned below, the peptide toxin that can be used for the inventive method is that same rHuAFP (or its fragment or analog) merges in conjunction with the territory by the molecule that produces a kind of a kind of hybrid protein of encoding.
A lot of peptide toxin have general eucaryon receptor binding domains; In this case, must modify in case leukorrhagia stopping has non-recipient cell to poison described toxin.Any described modification all must carry out with the form of the cytotoxicity function that can keep this molecule [referring to " U.S. Department of Health and Human Service; U.S.'s serial number 401.412 " (U.S.Department of Health and Human Service, U.S.SerialNo.401.412)].Potential useful toxin includes, but are not limited to: cholera toxin, ricin, O-shiga-like toxin (SLT-I, SLT-II, SLTII v), LT toxin, C 3Toxin, shiga toxin, pertussis toxin, PT, tetanus toxin, false monospore Bacillus extracellular toxin, saporin, modeccin and gelanin.
If desired, the cytotoxicity part that can be used for some molecule of the present invention can provide by mixing lps molecule.Mixing lps molecule is the molecule that comes from two kinds of different polypeptide toxins.Generally, as mentioned above, except determining the bonded domain of general eukaryotic cell, polypeptide toxin also has an enzymatic activity domain and a translocation domain.This binding structural domain and translocation domain are respectively cell recognition and toxin, and to enter institute essential.In case lps molecule enters cell, by described enzymatic activity domain decision cellular cytoxicity activity.
Known native protein with translocation domain comprises diphtheria toxin, diphtherotoxin, false monospore Bacillus exotoxin A and other possible peptide toxin.Prove absolutely the feature of the translocation domain of diphtheria toxin, diphtherotoxin and false monospore Bacillus exotoxin A is existing [for example, referring to Hoch etc., " institute of NAS periodical " be 82:1692 (Proc.Natl.Acad.Sci.USA), and 1985; Colombatti etc., " journal of biological chemistry " (J.Biol.Chem.) 261; 3030,1986; With Deleers etc., " European biochemistry association community communication " (FEBS Lett.) 160:82,1983], and, can (" cell " be 48:129 (Cell) with Hwang etc., 1987) and the method that adopted of Gray etc. (" institute of NAS periodical " be 81:2645 (Proc.Natl.Acad.Sci.USA), 1984) measure existence and the position of this domain on other molecule.
For example, a kind of useful rHuAFP/ mixing toxin hybrid molecule is by with the enzymatic activity A subunit of colon bacillus shiga sample toxin (for example, referring to Calderwood etc., " institute of NAS periodical " be 84:4364 (Proc.Natl.Acad.Sci.USA), 1987) merge with the translocation domain (amino acid residue 202-460) of diphtheria toxin, diphtherotoxin and rHuAFP and form.This rHuAFP that the heterozygote of 3 parts arranged partly makes this molecule can specific bond have can be by the cell of the receptor of rHuAFP identification, and the effect of diphtheria toxin, diphtherotoxin transhipment part to be enzymatic activity A subunit with shiga-like toxin insert in the target cell.The same albumen combination mechanism that acts on cell of enzymatic activity part of shiga-like toxin with diphtheria toxin, diphtherotoxin, synthetic to stop albumen, thus kill this cell.
The functional moiety of hybrid cell toxin of the present invention is by non-covalent bond or covalent bond or linked together by the two simultaneously.Non-covalent interaction can be ion-type, hydrophobic type or hydrophilic, and this interaction relates to that leucine-slide fastener interacts or antibody-Protein G interacts (for example, referring to Denick etc., " nature " be 359:752 (Nature), 1992).A covalently bound example is a disulfide bond.
The hybrid cell toxin be by with chemical method with rHuAFP (or fragment or analog) and any amount of known toxicity part, toxic component as indicated above is puted together and is made.This reaction is with well known to a person skilled in the art that standard technique carries out.With a kind of albumen and a kind of proteotoxin (for example, comprise bacteriotoxin, as diphtheria toxin, diphtherotoxin or false monospore Bacillus exotoxin A, or phytotoxin, as ricin) common method of puting together be crosslinked action by a disulfide bond realize (for example, referring to Chang etc., " journal of biological chemistry " be 252:1515 (J.Biol.Chem.), 1977) or by different basic bifunctional molecule (for example realize, referring to Cawley etc., " cell " (Cell), 22:563,1980).These can be referring to Stevens etc., U.S. Patent No. 4,894,227.
In addition, described hybrid cell toxin by the technology understood with those of ordinary skills [for example is, referring to Murphy, U.S. Patent No. 4,675,382 and Chadhary etc., " institute of NAS periodical " be 84:4538 (Proc.Natl.Acad.Sci.USA), and 1987] express with the coding rHuAFP (or its fragment or analog) of engineering method generation and the hybrid DNA of toxin (or its toxicity part) and make.For example, with the recombination fusion protein of approach well known (for example, referring to Murphy, the same and Huston etc., " Enzymology method " be 203:46 (Meth.Enzymol.), 1991) preparation rHuAFP and cytotoxic agent.If the hybrid cell toxin is to produce by expressing a fusion gene, between cytotoxic agent and target ligands, play interconnect function by a peptide bond.Can be used for the method that a kind of albumen or polypeptide and a kind of proteotoxin are puted together has been adopted polymer, mono methoxy polyethylene glycol (mPEG) [as described in Maiti etc., " international journal of cancer supplement " (Int.J.Cancer Suppl.) 3:17,1988].
If desired, behind synthetic hybrid cell toxin, it is carried out affinity purification, adopt the antibody of the target part of anti-this molecule with standard method, for example, the antibody of anti-human a-fetoprotein.Similarly, also can use the antibody purification hybrid cell lps molecule of anti-cell toxic agents by the immunological technique of standard.Then resulting hybrid cell toxin is mixed with as the preparation that resists such as harmful cell of cancerous cell, adopts the standard method of pharmaceutical field to be prepared.
Can use analytical method well known in the art, reduce the blodynamic ability of the cell that has the target receptor as disclosed in this article method screening molecule of the present invention.
Because hybrid cell toxin of the present invention is that have can be by the effective toxicity agent of the cell of the receptor of rHuAFP identification, so, rHuAFP can be used for the treatment of and relate to deleterious afp receptor positive cell, as the disease of cancerous cell.
Diagnostic agent
Reorganization rHuAFP or its fragment or analog can be combined with detectable labelling, make can be used for that body is interior, the preparation of original position or vitro detection and positioning tumor.The method that is used for this labelling is connected on the albumen is known in the art.For example, can connect detectable labelling, but when labelling is polypeptide, also can connect with gene engineering with chemical method.
Detectable labelling generally is selected from multiple this type of labelling known in the art, but common radiosiotope, fluorogen, enzyme (for example, horseradish peroxidase) or other part or the chemical compound that can launch the part or the chemical compound (as radioactivity, fluorescence, color) of detectable signal or after this labelling contacts its substrate, can launch detectable signal.Various detectable labelling/substrates to (for example, horseradish peroxidase/diaminobenzidine, Avidin/chain poison Avidin, luciferase/luciferin, beta galactosidase/X-gal (5-bromo-4-chloro-3-indyl-D-galactopyranoside) and for the method for this testing goal labelled protein be known in the art.Can measure the purposes of this preparation with the following method: for example, to implant host such as the tumor cell line of MCF-7, and detect preparation of the present invention by the radiation visualization techniques that adopts the scintiphotograph method and whether can detect ground mark by the tumor of implanting that cell produced such as mice.Also this preparation can be used to detect whether have any deleterious cell that has afp receptor, for example, adopt the Western engram analysis or tissue sample is carried out histochemical stain with known method.
HuAFP is as anticarcinogen in reorganization
Anticarcinogen of the present invention is (as rHuAFP or its fragment or analog; Or the hybrid cell toxin of rHuAFP) can be used for suppressing tumor, as breast carcinoma or carcinoma of prostate.It will be understood by those skilled in the art that any method that is used for the effect of mensuration anticarcinogen in external and the body all can be used for the present invention.For example, long mice or the minimizing of the tumor growth of mice greatly that carcinoma of prostate (for example, the tumor xenotransplantation of the positive human prostate cancer cell line of LNCaP androgen receptor) is arranged of monitoring after the medicine-feeding test chemical compound.In one embodiment, by trypsinization will grow in the culture the human tumour cell line [for example, such as MCF-7 (ATCCHTB 22), T-47D (ATCC HTB 133), MDA-MB-231 (ATCC HTB 26), BT-20 (ATCC HTB 19), NIH:OV-CAR-3 (ATCCHTB 161), Ln Cap.FGC (ATCC CRL 1740) and Du-145 (ATCC HTB 81) disengage from cell monolayer, be diluted to single-cell suspension liquid, and by the centrifugal precipitation that is solidified into, then, following at 37 ℃ with 15 μ l fibrinogens (50mg/ml) and 10 μ l thrombins (50 units/ml) handled 30 minutes.The fibrin piece that will contain tumor then is cut into the fritter that diameter is about 1.5mm.Each tumor mass is implanted below the scrotum of mice with standard method then.If desired, can soon begin mice to be carried out immunosuppressant before the implantation tumour with conventional method subcutaneous injection every day (S.C.) 60mg/kg cyclosporin A (Sandimmune IV).If desired, with standard method mice is carried out estrogen and androgen and replenish, for example implant the silication rubber tube or the injection Testosterone Propionate that contain estradiol.Usually, hormonal supplementation starts from the same day of tumour transplatation.Generally, the use of test molecule is to begin before tumour transplatation and/or after the tumour transplatation.Control animals receive placebo, as human albumin or diluent, with administration rHuAFP or the similar mode administration of correlation molecule placebo.With of the influence of any standard method monitoring test molecule to tumor growth.For example, measure the mode of tumor size by laparotomy weekly and monitor growth of tumor, adopt the anatomic microscope that is equipped with eyepiece micrometer.Proof can stop or weaken or the molecule that suppresses the tumor growth of this transplanting is considered to can be used for the present invention by experiment.
Can be by the toxicity of the cell of the receptor of rHuAFP identification at the external test test compound to having with any standard method.For example, with the cancerous cell line of cultivating, maintain as MCF-7 estrogen receptor-positive human breast cancer cell line in the improvement Eagle culture medium (DMEM) of the Dulbecco that contains in plastics tissue culture flasks (Costar), contain penicillin (100U/ml), streptomycin (100 μ g/ml), 5% hyclone, insulin (10ng/ml), L-glutaminate (2mM) and nonessential aminoacid (1%) among the DMEM.With 1 * 10 5The concentration in/hole is inoculated into that (Linbro-FlowLaboratoris, Mclean is in complete medium VA) on the plate at the bottom of the 96 hole V-arrangements.With various concentration (10 -12M-10 -6M) add the toxin infer, and under 37 ℃ at 5% CO 2In the gas culture was cultivated 18 hours.After the cultivation,, remove culture medium in the centrifugal described plate of 170xg 5 minutes, and replace 100 μ l do not have leucic culture medium (MEM, Gibco), this culture medium contain 8 μ Ci/ml ( 3The H-leucine; NewEngland Nuclear, Bostoa, MA).Under 37 ℃, cultivated again 90 minutes, and with the centrifugal described plate of 170xg 5 minutes, removed culture medium then, and with cell harvestor (Skatron, Sterling, VA) with cell harvesting on glass fiber filter.Washing filter membrane, drying also counted with standard method.With the cell of only using culture medium culturing in contrast.Compare with untreated control cells, to as toxicity indication can weaken or prevention or cytostatic test compound are measured, and be regarded as can be used for the present invention.
Measure method that whether a kind of test compound can produce the protective effect that antitumor (breast carcinoma or carcinoma of prostate) takes place and (for example relate generally to use a kind of known animal that can produce tumor; in U.S. Patent No. 4; transgenic mice disclosed in 736,866).Handle suitable animal by standard method with test compound, and the reduction of sickness rate of detected and untreated control animal being compared tumor invasion is as the indication of protective effect.
As mentioned below, the inventor has found that the non-glycosylated rHuAFP that produces can effectively treat cancer in prokaryotic expression system.For example, have found that rHuAFP is the effective inhibitors of the breast carcinoma of growth in vitro.
The experimental example that discloses has below confirmed the effectiveness of rHuAFP as anticarcinogen.These experimental examples are to be used to illustrate of the present invention, rather than will limit the present invention.
Embodiment
Material and method
Culture medium and tumor cell
Buy Dulbecco ' s improved Eagle ' s culture medium (DMEM), RPMI1640, hyclone, glutamine, non essential amino acid and penicillin-Streptomycin mixture from GIBCO (BRL).The donor Ox blood serum is available from Hyclone, Logan, and UT, and Iletin II (Lilly) is available from Squibb, Inc., Princeton, NJ.
MCF-7 estrogen-receptor-positive human breast cancer cell line is by Institute ofExperimental Biology and Medicine, Buenos Aires, and Argentina Alberto doctor C.Baldi provides.Female culture is maintained among the DMEM that is contained in the plastics tissue culture flasks (Costar), and this DMEM contains penicillin (100u/ml), streptomycin (100 μ g/ml), 5% hyclone, insulin (10ng/ml), L-glutaminate (2mM) and non essential amino acid (1%).
Grow in the be paved with back of the MCF-7 cell that estrogen stimulates in cultivation.
This test is based on following discovery: the MCF-7 cell is grown in containing estrogenic culture medium through being paved with the phase, and builds up into centrostigma; But, lacking under the estrogenic condition, cell proliferation stops after forming cell-cells contacting in the culture, (for example can not form centrostigma, referring to Gierthy etc., " the research treatment of breast carcinoma " (Breast Cancer Res.2Treat.) 12:227,1988).With 1 * 10 7The MCF-7 breast cancer cell is inoculated in the 16mm hole of 24-hole tissue culturing plate.Culture medium is no phenol red DMEM, 5% donor Ox blood serum (screening in advance can detect estrogenic shortage), L-glutaminate (2mM), non essential amino acid (1x have wherein been replenished, GIBCO), (1x GIBCO) is diluted to 1.8 * 10 with final concentration for insulin (10ng/ml), penicillin-streptomycin -9The estradiol of M.In the time of 24 hours in culture supplementing culture medium, replenished once in per subsequently 4 days, replenish the culture medium that 2ml contains rHuAFP and human serum albumin at every turn, the final protein concentration that makes every hole is 100 μ g/ml.Cell reached in 5 days and is paved with, and occurred a large amount of centrostigmas in 10 days in only containing estrogenic hole.Also dye with buffered formalin fixed cell with 1% rhodamine B.With an Artek 870 Macro-MicroAutomated Colomy Counter painted centrostigma is carried out quantitatively.Given data are the number of the average centrostigma of each processed group.
The result
The anti-MCF-7 breast cancer cell of rHuAFP activity
Result shown in Figure 9 shows that the MCF-7 breast cancer cell that rHuAFP can suppress estrogen and stimulate is grown in the external back that is paved with.Adopt human albumin or protein free control experiment that the formation of MCF-7 centrostigma is not had influence.Above data shows that rHuAFP has direct repression to the growth of cancerous cell culture.
The treatment administration
As mentioned above, rHuAFP can effectively suppress tumor, for example, and the mammary glandular cell cancer.Therefore, can with known method with chemical compound of the present invention be mixed with can be medicinal compositions.Can treat human patients with the rHuAFP anticarcinogen that is contained in the treatment effective dose in the last acceptable carrier of physiology.Suitable carriers and the prescription by E.W.Martin be disclosed in Remington ' s " pharmacy " (PharmaceuticalSciences) in.The dosage of anticarcinogen is different because of the type of administering mode, patient's age and body weight and disease.Generally, its consumption but, needs lower consumption in some occasion, because the specificity of this chemical compound is higher in the amount ranges of other preparation that is used for the treatment of cancer.For example, as mentioned below, can suppress the sosimetric system administration rHuAFP of malignant cell propagation, dosage range is generally the 0.1ng-10g/kg body weight.
In addition, method of the present invention also can adopt combined therapy, wherein administration simultaneously of rHuAFP and chemotherapeutics or administration successively.Generally, with standard method administration chemotherapeutics, perhaps, use chemotherapeutics to be lower than single dosage with chemotherapeutics.The example of chemotherapeutics includes, but are not limited to chlormethine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, the hexamethylol melamine, thiotepa, busulfan, carmustine, chlorethyl cyclohexyl nitrosourea, semustine, streptozotocin, dacarbazine, methotrexate, fluorouracil, cytosine arabinoside, purinethol, thioguanine, penta inhibin, vincaleucoblastine, vincristine, etoposide, podophyllotoxin, actinomycin D, daunomycin, amycin, bleomycin, plicamycin, mitomycin, cisplatin, mitoxantrone, the hydroxyl urea, procarbazine hydrochloride, mitotane, aminoglutethimide, prednisone, hydroxyprogesterone, diethylstilbestrol, zitazonium, flutamide, or gonadotropin releasing hormone analogues.
Treat general self diagnosis when going out tumor or suspection tumor being arranged, normally every day repeated drug taking.Administration every day rHuAFP also can prevent the generation of tumor.If desired, whether cancered method is estimated the effect of treatment or protection scheme with monitoring or diagnose the patient.
In addition, chemical compound of the present invention also can be used for treating mammal, to kill any relevant with the pathology symptom, deleterious, cell of having afp receptor.The inventive method also can be used for treating non-human mammal, for example, and domestic animal or domestic animal.As mentioned below, anticarcinogen of the present invention can be administered systemically or topical.
Be administered systemically
Chemical compound of the present invention can be administered systemically when being used as anticarcinogen, for example, is mixed with pharmaceutically acceptable buffer, as normal saline.For instance, that the method for optimizing of administration comprises is subcutaneous, intravenous, intraperitoneal, intramuscular or intradermal injection, in this way keeps the intravital levels of drugs of patient continuously.In other preferred medication, can for example, described chemical compound be imported in patient's body by a kind of slow releasing preparation of injection with slow dissociated polymerization or crystal form; Before this mode that continues medication, can be with more common method (for example, as indicated above method) beginning administration.In addition, can be with inculcating the described chemical compound of pump administration, so that accurate control drug release speed, or be used to promote the mode of absorption of insulin that described chemical compound is put into nasal meatus to be similar to.As a kind of alternative, can chemical compound of the present invention be imported pulmonary with the aerosol precipitation or the solution form of powder through Nasal Mucosa Absorption.
Topical
Anticarcinogen of the present invention also can topical, with the treatment cancer.Because the size of the tissue that relates to is depended in the effect of desirable therapeutic agent usually, for example, the size of tumor, it is ideal especially therefore carrying medicine near the mode that can cause having the tumor very high local concentration.
To recombinate HuAFP as diagnostic agent
Be used for diagnostic purpose at the reorganization HuAFP (or its fragment or analog) that detects, monitors or analysis tumor (for example, breast carcinoma or carcinoma of prostate) can be connected with certification mark when existing.
For example, can carry out studying in the body to human patients, to determine existing of tumor with the rHuAFP that can detect ground mark (rHuAFP of Tc-99m-labelling).Generally, intravenous administration can detect the rHuAFP of ground mark, and carries out video picture by method known to those skilled in the art with scanner, for example, carries out the radioactivity video picture with the scintiphotograph method.
In another embodiment, can be with the rHuAFP (or its fragment or analog) that is connected with a kind of certification mark detection such as tumor in the tissue sample of living tissue, body fluid or any existence that has the cell of the receptor that can discern by rHuAFP.Through after the above mensuration, should check the existence of this cell in tissue sample, living tissue or humoral sample, particularly lymph, blood, serum or the urine of taking from the patient.Therefore, can or exist with the cell of fractionated (for example,, the same by the Subcellular Localization of the receptor of rHuAFP identification referring to Ausubel etc. by any standard biochemistry or histochemical method; Bancroft and Stevens, " theory and practice of histological techniques " (Theory and Practice of HistologicalTechniques), Churdill Livingstone, 1982) carry out original position or external test.The appropriate control sample that is used to analyze comprises tissue sample or the body fluid of gathering (negative contrast) in the individuality that does not have the cell that has alpha-fetoprotein, or contains sample (over against shining) known, the predetermined quantity afp receptor.
Diagnostic test can be with any standard method in solution or with solid (insolubility) support (for example, polystyrene, celluloid or beadlet) or carry out in the tissue sample for preparing for histological examination.For example, in order to determine whether on one's body it patient of acquisition test sample has that have can be by the cell of the receptor of rHuAFP identification, with the rHuAFP that can detect ground mark in the test specimen in conjunction with level with its negative control sample and/or just the level that combines in the control sample compare.When in test specimen being higher than in conjunction with level in negative control sample bound water at ordinary times, or equal at least in positive control sample bound water at ordinary times, show that this patient has the cell that carries afp receptor.
Be used for being undertaken the material of diagnostic analysis, can provide with the kit form that has operation instruction by the inventive method.Generally, this test kit partly is made up of rHuAFP (or its fragment or analog).This test kit can also comprise another kind of reagent, for example, is used to the certification mark of labelling rHuAFP (or its fragment or analog).For example, the mentioned reagent box can be used for the existence of tumor in the vitro detection tissue sample, or is used for testing goal in the body.
Experiment example described below has confirmed the effect of rHuAFP diagnosing tumour.
Embodiment
Material and method
Animal
Use means known in the art, making the MCF-7 mankind mastopathy cell who implants CB-17 SCID mice pleurobranch portion grow to diameter under the estrogen incentive condition is 1cm size (about 5 grams).
Mtc labeled
By with 0.5ml 0.9% NaCl injection (Baxter Healthcare Corporation, Deerfield, IL) the reorganization alpha-fetoprotein of blended AFP specimen preparation 99m Tc labelling.Above-mentioned solution is added UltraTagRBC Reaction Vial (Mallinckrodt Medical Inc., St.Louis, Mo 63134 LotNo.0683040) in, wherein contain stannous chloride dihydrate, Trisodium citrate dihydrate and the anhydrous glucose of the lyophilized form of under argon, preserving.By slightly reverberating, mix the inclusions in the above-mentioned bottle, and incubation 5 minutes at room temperature.When incubation finishes, add volume and be 1-2ml 0.8-1.2GbqTechnetium 99mTc Sodium Pertechnetate Injection (99mTc Generator MallincroletMedical, Inc.St.Louis, MO).By slightly reverberating, mix the content in the above-mentioned bottle, and incubation 15 minutes.0,3 and 6 hour analysis dosage form sample after preparation.(GelmanInstrument Co., Ann Arbor MI) carry out thin layer chromatography with 0.9% NaCl to preparation, show that the 99Tc that 95-99% is arranged is bonded on the reorganization alpha-fetoprotein with ITLC-SG.
Video picture
With the calm laboratory animal of Medafane.Then one 24 footpath meter, 3/4 inch conduit (SurfloIV conduit, Terumo Medical) are fixed on the side direction tail.Slowly import 20-25mg/kg body weight pentobarbital by intravenous then above-mentioned animal is done further anesthesia.Optionally by injection 5mg pentobarbital maintenance anesthesia in addition, so that retrain its action.
Collect isotopic bio distribution data with Elscint Dymax 409 gamma cameras.Use computer (Siemans Gammasonics Microdelta) to analyze these data subsequently.Animal is carried out 3 video pictures, and animal is placed on the polyethylene thin plate with the posture of back of the body recumbency.For fear of animal activity during video picture, can retrain animal in case of necessity, with adhesive tape its limbs are tied up on above-mentioned plate, so that can not limit its breathing.The bio distribution that 60 minutes the dynamic image that is obtained is used to measure labelled protein.Usually, obtain 5 minutes images of 12 width of cloth order, and 1.5 hardware are zoomed into the computer matrix with 128 * 128 pixels with the calibration of low-yield general objects.The albumen of the Tc-99m labelling of 37MBq is injected in research usually with animal.
The result
Tracer bio distribution and kinetics
At administration 37MBq from the tail arteries and veins (about 4-6 μ g Tc-99m recombinant human alpha-fetoprotein) afterwards, 1 hour and the 24th hour chorologic kinetics of mensuration tracer after injection.Measure with 60% form (%IA) of interested position, activity/100 (ROI, the Region of Interested) pixel of injection and to organize absorption dynamics.In first hour, can eliminate from kidney rapidly, moderate is positioned liver, and in other organ obvious activity is arranged seldom.In the time of first hour, tumor is absorbed as (average ± SEM:1.9 ± 0.3% IA), and tumor and heart (T/H) position ratio is 0.84 ± 0.23.During by 24 hours, tumor is absorbed as (0.8+/-0.1% IA) and the ratio of T/A and tumor and background (the last breast of T/B) part is respectively 1.43 ± 0.41 and 2.66 ± 0.54.Comparative study to the rHuAFP of the 99mTc-labelling that repeats on identical animal and the human serum albumin of 99mTc-labelling (as non-differential protein contrast) shows, rHuAFP for the 99mTc labelling, T/B image ROI specific activity when 1 hour and 24 hours is respectively 2.7 and 5.8, and the specific activity Tc-99m human serum albumin of the rHuAFP of 99mTc labelling is high by 40% in the time of 24 hours.Above result shows that rHuAFP can use the Tc-99m labelling, and the preparation of this labelling has the low non-specific absorbing power of organizing and also can be removed from blood rapidly by kidney.Location in human breast cancer xenotransplantation body is originally very fast, and passes in time and accelerate, and this is because special tumor absorbs.These results show, can be used as the diagnostic agent of breast carcinoma with the rHuAFP of Tc-99m labelling.
Diagnostic uses
As mentioned above, the rHuAFP that is connected with detectable labelling (or its fragment or analog) can be used for diagnostic purpose, is used for detection, monitoring or the analysis of tumor (as the mammary glandular cell cancer).Therefore, typical cancer symptoms occurs, as the patient of breast carcinoma or carcinoma of prostate symptom, or the patient with the medical history taking that shows this cancer of easy trouble can test with the inventive method.Other patients that are fit to this test comprise that those have the patient of breast carcinoma or carcinoma of prostate family history.Also should check the patient that just accepting medicine or be related to the patient that detoxifying function that cancer brings out is crossed.
The diagnostic method that has adopted the rHuAFP (or its fragment or analog) that can detect ground mark and cross of the present invention is used in the existence that detection cancer before or after the clinical symptoms relevant with cancer occurs.
Method of the present invention help occur clinical symptoms (as palpable lump) before with the while diagnosing tumour.For example, subject methods of the present invention is used in and clinical symptoms diagnosing mammary cancer before occurs.In addition, method of the present invention can make the doctor accurately diagnose out tumor such as breast carcinoma or carcinoma of prostate.
Diagnostic imaging method of the present invention can be carried out with the rHuAFP diagnostic agent that is contained in the diagnosis effective dose in the acceptable carrier on the physiology.For example, suitable carriers and prescription thereof are disclosed in " Remington ' s pharmacy " (Remington ' s Pharmaceutical Sciences) by E.W.Martin.The amount of desiring the diagnostic agent of administration depends on following factor: the degree that spreads of the type of administering mode, patient's age and body weight, disease, disease and the build of suffering from the patient of this disease.But, general consumption is in other is used for the amount ranges of preparation of cancer diagnosis, although need lower consumption in some occasion, this is because it has higher compound specificity.For example, the rHuAFP that can detect ground mark for above-mentioned patient's administration in the intravenous injection mode is so that the dosed administration that tumor can video picture for example, is looked into method with the flicker photograph and carried out the radioactivity video picture.Usually, dosage is in the 0.1ng-10g/kg weight range.
Mentioned in this manual all publications, patent and patent application all made the reference material of this paper with the deal that equates by receipts, is indicated as being particularly or individually to receive as every part of publication or patent application and does reference of the present invention.
Cell culture medium of the present invention
The present invention also provides the culture medium that contains rHuAFP (or its fragment or analog) that is used for cell culture.Though culture medium of the present invention does not generally need to use serum (for example, hyclone, Ox blood serum, horse serum, normal mouse serum, human serum, porcine blood serum, rabbit anteserum etc.), because desire is used to described rHuAFP to replace or the purposes of additional serum, but those skilled in the art are to be understood that, if desired, can add serum.Joining foster basic composition generally prepares with approach well known.Therefore, any standard medium can be prepared with rHuAFP (or its fragment or analog) with the valid density of needs as RMPI-1630 culture medium, CMRL culture medium, the improved Eagle culture medium of Dulbecco ' s (D-MEM), Fischer ' s culture medium, the improved Dulbecco ' of Iscove ' s s culture medium, Mccoy ' s culture medium, minimum essential medium, NCTC culture medium etc.If desired, add the culture media supplemented composition with known method, for example, saline solution (as Hank ' s balanced salt solution or Earle ' s balanced salt solution), antibiotic, nucleic acid, aminoacid, saccharide and vitamin.If desired, can also there be standard method in culture medium, to add somatomedin, colony stimulating factor, cytokine etc.For example, culture medium of the present invention can contain following any material and rHuAFP (or its fragment or analog) separately or with combining form: erythropoietin, granulocyte/M-CSF (GM-CSF), granulocyte colony-stimulating factor (G-CSF), M-CSF (M-CSF), interleukin (as IL-1, IL-2, IL-3, IL-4, IL-5 etc.), insulin-like growth factor (IGF), transferrin, albumin and stem cell factor (SCF).Culture medium of the present invention can be used for cultivating multiple eukaryotic cell, as mammalian cell, yeast cells, amphibian cell and insect cell.Culture medium of the present invention can also be used to cultivate any tissue or organ.Described culture medium also can be used for multiple condition of culture, and is used for the various biological purpose.The example of described condition of culture includes, but are not limited to bioreactor (as successive or hollow-fiber bioreactor), cell suspension culture, semi-solid culture and long-term cell suspension culture.Culture medium of the present invention also can be used for industrial use, for example, cultivates hybridoma, genetic engineering mammalian cell, tissue or organ.
With recombinant human alpha-fetoprotein as cell proliferating agent
With any cell growth-promoting effect that is used for the determination of test method rHuAFP (or its fragment or analog) of external and body inner analysis cell proliferation.As mentioned below, this area is useful on the cell growth of in vivo test rHuAFP (or its fragment or analog) or promotes the animal system of feature.In addition, also have multiple can be used for the testing growth of rHuAFP (or its fragment or analog) or the vitro system that feature is promoted in growth.
Can identify that any effect is in rHuAFP (or its fragment or analog) and proliferating cells with standard method known in the art.For example, can monitor cell (as medullary cell) propagation like this: cultured cell in containing the fluid medium of test compound, with test compound separately or artificially to add serum-free or serotonin culture medium with other combinations of. growth factors form.In addition, can in the semisolid matrix of rare agar or methylcellulose, cultivate described medullary cell, and with test compound separately or being to join in the culture medium that serum-free or serum reduced with other combinations of. growth factors form people.In described semisolid matrix, the filial generation effect of isolating precursor keeps together with identifiable colony in rHuAFP or its fragment or analog propagation.For example, a medullary cell can form the clone who is made up of a plurality of medullary cells, described cell such as NK cell.This system provide a kind of cell of a kind of analysis whether individual effect in rHuAFP (or its fragment or analog) or effect in the convenient method of the combination of rHuAFP and other somatomedin.
If desired, identify according to standard method and separation expanded cells subgroup.For example, can use fluorescence-activated cell sorter (FACS) analysis of cells.This method generally comprises to be used and the bonded antibody labeling cell of fluorescent dye, and labeled cell is separated described FACS such as FACScan (Becton Dickson) on a FACS with unlabeled cells.Therefore, by the existence of analysis of cells surface antigen, in fact can identify and separate (for example, referring to Shah etc., " Journal of Immunology " be 140:1861 (J.Immunol.), 1988) any cell.When obtaining a cell mass, it is carried out biochemical analysis, or with its initial population as another time cell culture, so that can under the condition that condition of culture is determined, the effect of pair cell measure.
In one embodiment, check the effect of rHuAFP (or its fragment or analog) with the following method to human bone marrow cell's growth.Generally, human bone marrow's sample is to obtain with standard method in the back that secures permission.For example, bone marrow is to obtain from the crista iliaca of healthy donors, and at room temperature medullary cell is diluted in the saline solution of phosphoric acid buffer.Washed cell and it is grown in suitable growth medium then.For example, can cultivate by medullary cell being seeded in set up in the McCoy ' s culture medium that 20-30ml contains 50U/ml penicillin, 50U/ml streptomycin and 2mM L-glutaminate.Be with or without individualism or with such as the condition of other combinations of. growth factors of transferrin or GM-CSF under cultivate described culture.Under 37 ℃, containing 5% CO subsequently 2, 5% O 2With 90% N 2Humid air in culture is cultivated, continue the needed time.Carry out cell proliferation test with standard method.For example, by using 1-2 μ Ci's 3HTdR pulse cell is to analyzing at the replicate sample that has and do not have to cultivate under the condition of test compound.Through certain culture after the time, culture gathered in the crops on the glass fiber filter and measure and mix by liquid scintillation 3H.To cell and the control cells of handling,, use it for the relative effectivenes of determination test molecule aspect stimulating cellular proliferation as cultured cells compares research under the cultured cells and the condition at no rHuAFP having under the condition of rHuAFP.The molecule that can stimulate cellular proliferation is regarded as can be used for the present invention.
In order to measure the proliferation function of rHuAFP (or its fragment or analog), for example, hemopoiesis in the body of test compound, use standard method such as intravenous injection or peritoneal injection, (or use immunosuppressant to give suitable dose every day the inferior radiation murine that causes death such as cyclosporin or FK-506, or use chemotherapeutics, or the mice of handling with the method for any other dilution bone marrow known in the art) and normal mouse medicine-feeding test molecule such as 5-fluorouracil or cyclophosphamide.Generally, to give the mice medicine-feeding test chemical compound handled be before using such as the Asia deadly radiation, immunization therapy or amic therapy method processing animal and/or begin afterwards.The placebo of control animals received such as human serum albumin or diluent, with administration rHuAFP or the similar method administration of correlation molecule placebo.With of the effect of standard technique monitoring test molecule to hemopoietic.For example, the white blood cell count in peripheral blood of analyzing and processing animal and control animal and the spleen.Bone marrow such as lymphocyte pedigree or bone marrow pedigree or any other cell type is carried out qualitative and quantitative analysis, also can measure and analyze with conventional method.Animal that comparison process is crossed and the data of control animal, and use it for the relative effectivenes of determination test molecule aspect the promotion cell proliferation, for example, promote medullary cell generation, ripe bone-marrow-derived lymphocyte, thymocyte cell or peripheral T lymphocyte to produce.The test molecule that can stimulate cellular proliferation is regarded as can be used for the present invention.
Following examples have confirmed the ability of non-glycosylated rHuAFP in the growth of stimulated in vitro bone marrow.This embodiment has used explanation of the present invention, rather than will limit scope of the present invention.
Embodiment
Material and method
Animal
(Bar Harbor Maine) obtains bull and female CBA/J mice by the Jackson laboratory.All mices are all raised in our animal feeding device and keep.The animal that is used for this research is 12-20 age in week.
Culture
With tibia and the femur of the saline solution (PBS) of improved Dulbecco ' s phosphoric acid buffer flushing CBA/J mice, and with disinfectant syringe and 25-specification (gauge) syringe needle collection medullary cell.By allowing cell mixture from the Pasteur pipet, pass through to obtain uniform single-cell suspension liquid repeatedly.All cells by under 250xg in PBS centrifugal 10 minutes the washing 2 times, survey its vitality by the trypan blue dye excretion then.In all experiments, all record 95% or higher cell viability.Before using, cell is transferred to ideal concentration then.Microtitration plate at the bottom of 96 hole circles (Flow Laboratories, Mississauga, Ontario, Canada) the middle medullary cell (250,000) of cultivating.Culture medium for serum-free RPMI add 4mM L-glutaminate, 20mMHepes, 100u/ml penicillin, 100 μ g/ml streptomycins (GIBCOLaboratories, Burlington, Ontario, Canada), 5 μ g/ml transferrins and 5 * 10 -5Second-mercaptoethanol (Eastman Chemicals Co., Rochester N.Y.).Be cultured cell under the condition of rHuAFP of 400 μ g/ml not having rHuAFP or concentration being arranged respectively.The cumulative volume of all cultures is 0.2ml.Cell is 95% in temperature under 37 ℃, contain 5% CO 2Air in carry out.Results 6 hours are before carried out pulse with 1 μ Ci tritiate thymidine (NEN, specific activity 77.1Ci/mmol) to culture.Use then various product catcher (Skatron, Flow Labs) with cell harvesting on fiberglass packing (Flow Labs).Measure the incorporation of water-fast tritiate thymidine with LKB 1215 RackbetaII, by the normal fluid scintillation technique.
The result
RHuAFP in serum-free medium to myeloproliferative effect
In serum-free medium, measure the influence of purification rHuAFP to the Os Mus marrow of cultivation.In this embodiment, not or final concentration is arranged is that 400 μ g/ml and final concentration are will be available from 2.5 * 10 of CBA/J mice among the serum-free RPMI of transferrin of 5 μ g/ml 5Living cells was cultivated 72 hours.Data show shown in Figure 10, are having under the condition of non-glycosylated rHuAFP, and medullary cell can carry out significant breeder reaction; Stimulation index (SI) is 35.Do not observe this proliferation function there being under the condition of rHuAFP the medullary cell of cultivation.
Treatment
As mentioned above, rHuAFP can effectively promote cell proliferation, therefore, can be used for relating to the promotion cell proliferation, as the treatment of proliferation of bone marrow cells, and can be used for epidemic prevention inhibition therapy, radiotherapy or chemotherapy or other known meeting inhibition immune system and suppress the treatment that bone marrow produces the side effect of the therapy that causes bone marrow toxicity.Therefore, rHuAFP (or its fragment or analog) is used to treat protoerythrocyte CFU-GM or stem cell defect or relevant disease.Reorganization HuAFP (or its fragment or analog) also can be used for treating cancer and other causes other pathology symptom of bone marrow toxicity, treatment is subjected to radiation or drug effect, for example comprise leukopenia, antibacterial and viral infection, anemia, B cell or T cell defect, comprise the immunocyte or the protoerythrocyte defective of self or non-autologous bone marrow transplantation.Reorganization HuAFP (or its fragment or analog) also can be used for growth external or body internal stimulus megalokaryocyte and natural killer cell.
Culture medium of the present invention, compositions and method also can be used for the cancer that treatment is treated by bone marrow transplantation (BMT), this method comprises in patient's body takes out bone marrow, in the culture of ex vivo, keep these cells, simultaneously the patient is carried out radiotherapy or chemotherapy, and after treatment finishes, these cells are implanted in patient's body again, to recover patient's bone marrow.Therefore, rHuAFP can be used for BMT, as the means of rebuilding bone marrow in the cell culture medium of ex vivo, and is used for promoting in vivo the propagation of medullary cell.Reorganization HuAFP (or its fragment or analog) also can be used for other cell therapy, and for example cell amplification and/or gene therapy need the therapy of the cell culture of ex vivo.Reorganization HuAFP (or its fragment or analog) also can be used for preventing the repulsive interaction of self or ABMT.
The treatment administration
Available known method will recombinate HuAFP (or its fragment or analog) be mixed with can be medicinal compositions.Recombinant human alpha-fetoprotein, as rHuAFP (or its fragment or analog) preferably can effectively prevent or improve the dosage of the toxic symptom of marrow to patient's administration.The dosage of general 0.1ng/kg-10g/kg body weight is enough.For example, can with the treatment effective dose, be contained in the rHuAFP in the acceptable carrier on the physiology (or its fragment or analog) treatment human patients.For example, suitable carriers and prescription thereof are disclosed in the Remingtor ' s pharmacy (Remington ' s Pharmaceutical Sciences) by E.W.Martin.The consumption of rHuAFP depends on following factor: the type of administering mode, patient's age and body weight, disease, tend to suffer from or just suffering from this sick patient's build.For example, the method for optimizing of administration comprises oral administration, and subcutaneous, intravenous, intraperitoneal, intramuscular, percutaneous or intradermal injection continue to keep the intravital levels of drugs of patient thus.In other preferred medication, can or implant such as the slow dissociated method that aggregates into the slow releasing preparation of crystal form and give patient's administration rHuAFP by injection; This continue medication before, can be with more common method (as mentioned above) beginning medication.In addition, can be with external or implantablely inculcate pump administration rHuAFP, so that accurately control the rate of release of medicine, or be used to promote the mode of absorption of insulin that rHuAFP is put into nasal meatus to be similar to.As a kind of alternative form through Nasal Mucosa Absorption, aerosol precipitation or solution form that can powder be imported pulmonary with rHuAFP.
Treatment and composition for of the present invention also comprises with other human growth factor's administration.The example that is used for the cytokine of this purpose or cytagenin includes, but are not limited to the factor such as interleukin (IL-1), GM-CSF, G-CSF, M-CSF, tumor necrosis factor (TNF), transferrin and erythropoietin.Somatomedin such as Bcell growth factor, B cell differential factor or eosinophil differentiation factor also can be used for the administration with rHuAFP (or its fragment or analog).Can adjust above-mentioned dosage, with above-mentioned other composition in the compensation therapeutic combination.Can be controlled patient's progress with the conventional method monitoring.
Generally, treatment starts to be diagnosed out or suspects when bone marrow toxicity is arranged, and repeats regularly or repeat every day, to improve or to prevent the development or the deterioration of symptom.Administration rHuAFP also can prevent or prevent the development of bone marrow toxicity before morbidity.If desired, can measure treatment or preventive effect with the method for monitoring or diagnosis patient bone marrow toxicity.
The inventive method also can be used for treating non-human mammal, for example, and domestic animal or domestic animal.
Other embodiment
In other embodiments, the present invention includes with rHuAFP (or its fragment or analog) be used for the prevention or the treatment acquired immunodeficiency syndrome (AIDS).In order to measure rHuAFP or its fragment or analog immunosuppressive action to AIDS, i.e. this chemical compound prevention or improve the ability of the autoimmunization of AIDS is used such as the standard method of intravenous or peritoneal injection and is given suitable animal (as human patients) medicine-feeding test chemical compound every day with above-mentioned suitable dose.Generally, administration is before the AIDS outbreak and/or occurs beginning after the AIDS clinical symptoms.Control animals receive placebo, as the human serum albumin, with administration rHuAFP or the similar mode administration of correlation molecule placebo.With of the influence of standard method monitoring test chemical compound to AIDS.For example, can monitor the analysis that test compound is suppressed, prevents or improve the destruction of helper T cell.The comparative study of the animal of handling and control animal be can be used for the confirmed test chemical compound in prevention or improve relative effectivenes aspect the AIDS.The molecule that can prevent or improve (weaken, or suppress, or alleviate, or promote to alleviate) AIDS symptom is regarded as can be used for the present invention.
The present invention comprises that also the rHuAFP (or its fragment or analog) with the treatment effective dose is used to suppress the repulsive interaction that mammiferous organ (as heart, liver, lung, pancreas and kidney), tissue (as the collagen of skin, bone marrow, cerebral dura mater, bone, implantation, the bioreactor of implantation) or cell (as β islet cells, stem cell, hemopoietic cell, lymphocyte, neuroendocrine cell or adrenal cells) are transplanted.Described transplant organ, tissue or cell can come from any source, for example, this biomaterial can be isotype, isophenic, self, synthetic, artificial or genetic engineering.For example, when the patient is allograft, can adopt this method as from the receptor of the heart of another species or kidney the time.
In one embodiment, rHuAFP is to the immunosuppressive action of clinical transplantation, be that rHuAFP prevention or the ability of improving transplant rejection effect (for example, hyperacute rejection, acute cellular rejection and chronic rejection) are to use such as the standard method of intravenous injection or peritoneal injection to measure to the mode of NIH miniature pig administration rHuAFP every day with suitable dose.Generally, the administration of rHuAFP is to transplant, as beginning before the renal transplantation and/or after the migration process.Control animals receive placebo is as the human serum albumin, with the similar approach administration of administration rHuAFP.With the influence of standard method monitoring rHuAFP to transplant rejection.A kind of function that takes the form of transplant organ of repulsion process sustains damage, and for example, can monitor urine and discharge quantitative analysis.If desired, it is (for example, with the histochemistry or the immunohistochemical method of any standard, for example, referring to Ausubel etc., the same to carry out histological inspection to nephridial tissue; Bancroft and Stevens, the same), and the tissue sample that obtains by biopsy carried out microscope inspection, seeking the evidence of transplant rejection, form or the appearance of unusual lymphatic infiltration as chronic interstitial fibrosis, vascular thrombosis.The comparative study of the animal of handling and control animal be can be used for measuring rHuAFP in prevention or improve the relative effectivenes that suppresses aspect the repulsion.The reorganization HuAFP (or its fragment or analog) that can prevent or improve (weaken, or suppress, or alleviate, or promote to alleviate) transplant rejection symptom is regarded as can be used for the present invention.
All publications of in description of the present invention, mentioning, manufacturer's explanation, patent, and patent application received with same deal and made reference material of the present invention, specially received the reference of making this paper as every part of publication or patent application with indicating respectively.
Sequence table
(1) physical data:
(i) applicant: Murgita, Robert A.
(ii) denomination of invention: the expression and the purification of human cloning alpha-fetoprotein
(iii) sequence number: 20
(iv) address:
(A) addressee: Fish and Richardson P.C.
(B) street: 225 Franklin Street, Suite 3100
(C) city: Boston
(D) continent: MA
(E) country: USA
(F) by volume: 02110-2804
(V) computer-reader form:
(A) media types: floppy disk
(B) computer: IBM PC compatibility
(C) operating system: PC-DOS/MS-DOS
(D) software: Patent In Release #1.0, #1.30 version
(vi) current application materials
(A) application number: PCT/US96/---
(B) applying date: on January 24th, 1996
(C) classification:
(vii) application materials formerly:
(A) application number: 08/377,317
(B) applying date: January 24 nineteen ninety-five
(C) classification:
(A) application number: 08/377,311
(B) applying date: January 24 nineteen ninety-five
(C) classification:
(A) application number: 08/377,309
(B) applying date: January 24 nineteen ninety-five
(C) classification:
(A) application number: 08/377,316
(B) applying date: January 24 nineteen ninety-five
(C) classification:
(A) application number: 08/505,012
(B) applying date: July 21 nineteen ninety-five
(C) classification:
(viii) lawyer/agent's data:
(A) name: Clark, Paul T.
(B) number of registration: 30,162
(C) data/document number: 06727/003001
(ix) communications data:
(A) phone: (617) 542-5070
(B) fax: (617) 542-8906
(C) fax: 200154
(2) sequence 1 data:
(i) sequence signature:
(A) length: 21 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological structure: linearity
(ii) molecule type: DNA (genome)
(xi) sequence description: sequence 1
TGTCTGCAGG ATGGGGAAAA A
(2) sequence 2 data
(i) sequence signature:
(A) length: 18 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological structure: linearity
(ii) molecule type: DNA (genome)
(xi) sequence description: sequence 2
CATGAAATGA CTCCAGTA
(2) sequence 3 data
(i) sequence signature:
(A) length: 18 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological structure: linearity
(ii) molecule type: DNA (genome)
(xi) sequence description: sequence 3
CATAGAAATG AATATGGA
(2) sequence 4 data:
(i) sequence signature:
(A) length: 2022 bases
(B) type: nucleic acid
(C) chain: do not relate to
(D) topological structure: linearity
(ii) molecule type: albumen
(xi) sequence description: sequence 4
ATATTGTGCT TCCACCACTG CCAATAACAA AATAACTAGC AACCATGAAG TGGGTGGAAT 60
CAATTTTTTT AATTTTCCTA CTAAATTTTA CTGAATCCAG AACACTGCAT AGAAATGAAT 120
ATGGAATAGC TTCCATATTG GATTCTTACC AATGTACTGC AGAGATAAGT TTAGCTGACC 180
TGGCTACCAT ATTTTTTGCC CAGTTTGTTC AAGAAGCCAC TTACAAGGAA GTAAGCAAAA 240
TGGTGAAAGA TGCATTGACT GCAATTGAGA AACCCACTGG AGATGAACAG TCTTCAGGGT 300
GTTTAGAAAA CCAGCTACCT GCCTTTCTGG AAGAAGTTTG CCATGAGAAA GAAATTTTGG 360
AGAAGTACGG ACATTCAGAC TGCTGCAGCC AAAGTGAAGA GGGAAGACAT AACTGTTTTC 420
TTGCACACAA AAAGCCCACT GCAGCATGGA TCCCACTTTT CCAAGTTCCA GAACCTGTCA 480
CAAGCTGTGA AGCATATGAA GAAGACAGGG AGACATTCAT GAACAAATTC ATTTATGAGA 540
TAGCAAGAAG GCATCCCTTC CTGTATGCAC CTACAATTCT TCTTTCGGCT GCTGGGTATG 600
AGAAAATAAT TCCATCTTGC TGCAAAGCTG AAAATGCAGT TGAATGCTTC CAAACAAAGG 660
CAGCAACAGT TACAAAAGAA TTAAGAGAAA GCAGCTTGTT AAATCAACAT GCATGTCCAG 720
TAATGAAAAA TTTTGGGACC CGAACTTTCC AAGCCATAAC TGTTACTAAA CTGAGTCAGA 780
AGTTTACCAA AGTTAATTTT ACTGAAATCC AGAAACTAGT CCTGGATGTG GCCCATGTAC 840
ATGAGCACTG TTGCAGAGCA GATGTGCTGG ATTGTCTGCA GGATGGGGAA AAAATCATGT 900
CCTACATATG TTCTCAACAA GACACTCTGT CAAACAAAAT AACAGAATGC TGCAAACTGA 960
CCACGCTGGA ACGTGGTCAA TGTATAATTC ATGCAGAAAA TGATGAAAAA CCTGAAGGTC 1020
TATCTCCAAA TCTAAACAGG TTTTTAGGAG ATAGAGATTT TAACCAATTT TCTTCAGGGG 1080
AAAAAAATAT CTTCTTGGCA AGTTTTGTTC ATGAATATTC AAGAAGACAT CCTCAGCTTG 1140
CTGTCTCAGT AATTCTAAGA GTTGCTAAAG GATACCAGGA GTTATTGGAG AAGTGTTTCC 1200
AGACTGAAAA CCCTCTTGAA TGCCAAGATA AAGGAGAAGA AGAATTACAG AAATACATCC 1260
AGGAGAGCCA AGCATTGGCA AAGCGAAGCT GCGGCCTCTT CCAGAAACTA GGAGAATATT 1320
ACTTACAAAA TGAGTTTCTC GTTGCTTACA CAAAGAAAGC CCCCCAGCTG ACCTCGTCGG 1380
AGCTGATGGC CATCACCAGA AAAATGGCAG CCACAGCAGC CACTTGTTGC CAACTCAGTG 1440
AGGACAAACT ATTGGCCTGT GGCGAGGGAG CGGCTGACAT TATTATCGGA CACTTATGTA 1500
TCAGACATGA AATGACTCCA GTAAACCCTG GTGTTGGCCA GTGCTGCACT TCTTCATATG 1560
CCAACAGGAG GCCATGCTTC AGCAGCTTGG TGGTGGATGA AACATATGTC CCTCCTGCAT 1620
TCTCTGATGA CAAGTTCATT TTCCATAAGG ATCTGTGCCA AGCTCAGGGT GTAGCGCTGC 1680
AAAGGATGAA GCAAGAGTTT CTCATTAACC TTGTGAAGCA AAAGCCACAA ATAACAGAGG 1740
AACAACTTGA GGCTCTCATT GCAGATTTCT CAGGCCTGTT GGAGAAATGC TGCCAAGGCC 1800
AGGAACAGGA AGTCTGCTTT GCTGAAGAGG GACAAAAACT GATTTCAAAA ACTGGTGCTG 1860
CTTTGGGAGT TTAAATTACT TCAGGGGAAG AGAAGACAAA ACGAGTCTTT CATTCGGTGT 1920
GAACTTTTCT CTTTAATTTT AACTGATTTA ACACTTTTTG TGAATTAATG ATAAAGACTT 1980
TTATGTGAGA TTTCCTTATC ACAGAAATAA AATATCTCCA AA 2022
(2) sequence 5 data
(i) sequence signature:
(A) length: 590 aminoacid
(B) type: aminoacid
(C) chain: do not relate to
(D) topological structure: linearity
(ii) molecule type: albumen
(xi) sequence description: sequence 5
Thr Leu His Arg Asn Glu Tyr Gly Ile Ala Ser Ile Leu Asp Ser Tyr
1 5 10 15
Gln Cys Thr Ala Glu Ile Ser Leu Ala Asp Leu Ala Thr Ile Phe Phe
20 25 30
Ala Gln Phe Val Gln Glu Ala Thr Tyr Lys Glu Val Ser Lys Met Val
35 40 45
Lys Asp Ala Leu Thr Ala Ile Glu Lys Pro Thr Gly Asp Glu Gln Ser
50 55 60
Ser Gly Cys Leu Glu Asn Gln Leu Pro Ala Phe Leu Glu Glu Leu Cys
65 70 75 80
His Glu Lys Glu Ile Leu Glu Lys Tyr Gly His Ser Asp Cys Cys Ser
85 90 95
Gln Ser Glu Glu Gly Arg His Asn Cys Phe Leu Ala His Lys Lys Pro
100 105 110
Thr Ala Ala Trp Ile Pro Leu Phe Gln Val Pro Glu Pro Val Thr Ser
115 120 125
Cys Glu Ala Tyr Glu Glu Asp Arg Glu Thr Phe Met Asn Lys Phe Ile
130 135 140
Tyr Glu Ile Ala Arg Arg His Pro Phe Lsu Tyr Ala Pro Thr Ile Leu
145 150 155 160
Leu Ser Ala Ala Gly Tyr Glu Lys Ile Ile Pro Ser Cys Cys Lys Ala
165 170 175
Glu Asn Ala Val Glu Cys Phe Gln Thr Lys Ala Ala Thr Val Thr Lys
180 185 190
Glu Leu Arg Glu Ser Ser Leu Leu Asn Gln His Ala Cys Pro Val Met
195 200 205
Lys Asn Phe Gly Thr Arg Thr Phe Gln Ala Ile Thr Val Thr Lys Leu
210 215 220
Ser Gln Lys Phe Thr Lys Val Asn Phe Thr Glu Ile Gln Lys Leu Val
225 230 235 240
Leu Asp Val Ala His Val His Glu His Cys Cys Arg Ala Asp Val Leu
245 250 255
Asp Cys Leu Gln Asp Gly Glu Lys Ile Met Ser Tyr Ile Cys Ser Gln
260 265 270
Gln Asp Thr Leu Ser Asn Lys Ile Thr Glu Cys Cys Lys Leu Thr Thr
275 280 285
Leu Glu Arg Gly Gln Cys Ile Ile His Ala Glu Asn Asp Glu Lye Pro
290 295 300
Glu Gly Leu Ser Pro Asn Leu Asn Arg Phe Leu Gly Asp Arg Asp Phe
305 310 315 320
Asn Gln Phe Ser Ser Gly Glu Lys Asn Ile Phe Leu Ala Ser Phe Val
325 330 335
His Glu Tyr Ser Arg Arg His Pro Gln Leu Ala Val Ser Val Ile Leu
340 345 350
Arg Val Ala Lys Gly Tyr Gln Glu Leu Leu Glu Lys Cys Phe Gln Thr
355 360 365
Glu Asn Pro Leu Glu Cys Gln Asp Lys Gly Glu Glu Glu Leu Gln Lys
370 375 380
Tyr Ile Gln Glu Ser Gln Ala Leu Ala Lys Arg Ser Cys Gly Leu Phe
385 390 395 400
Gln Lys Leu Gly Glu Tyr Tyr Leu Gln Asn Glu Phe Leu Val Ala Tyr
405 410 415
Thr Lys Lys Ala Pro Gln Leu Thr Ser Ser Glu Leu Met Ala Ile Thr
420 425 430
Arg Lys Met Ala Ala Thr Ala Ala Thr Cys Cys Gln Leu Ser Glu Asp
435 440 445
Lys Leu Leu Ala Cys Gly Glu Gly Ala Ala Asp Ile Ile Ile Gly His
450 455 460
Leu Cys Ile Arg His Glu Met Thr Pro Val Asn Pro Gly Val Gly Gln
465 470 475 480
Cys Cys Thr Ser Ser Tyr Ala Asn Arg Arg Pro Cys Phe Ser Ser Leu
485 490 495
Val Val Asp Glu Thr Tyr Val Pro Pro Ala Phe Ser Asp Asp Lys Phe
500 505 510
Ile Phe His Lys Asp Lsu Cys Gln Ala Gln Gly Val Ala Leu Gln Arg
515 520 525
Met Lys Gln Glu Phe Leu Ile Asn Leu Val Lys Gln Lys Pro Gln Ile
530 535 540
Thr Glu Glu Gln Leu Glu Ala Leu Ile Ala Asp Phe Ser Gly Leu Leu
545 550 555 560
Glu Lys Cys Cys Gln Gly Gln Glu Gln Glu Val Cys Phe Ala Glu Glu
565 570 575
Gly Gln Lys Leu Ile Ser Lys Thr Gly Ala Ala Leu Gly Val
580 585 590 (2) sequences, 6 data:
(i) sequence signature:
(A) length: 197 aminoacid
(B) type: aminoacid
(C) chain: do not relate to
(D) topological structure: linearity
(ii) molecule type: albumen
Thr Leu His Arg Asn Glu Tyr Gly Ile Ala Ser Ile Leu Asp Ser Tyr
1 5 10 15
Gln Cys Thr Ala Glu Ile Ser Leu Ala Asp Leu Ala Thr Ile Phe Phe
20 25 30
Ala Gln Phe Val Gln Glu Ala Thr Tyr Lys Glu Val Ser Lys Met Val
35 40 45
Lys Asp Ala Leu Thr Ala Ile Glu Lys Pro Thr Gly Asp Glu Gln Ser
50 55 60
Ser Gly Cys Leu Glu Asn Gln Leu Pro Ala Phe Leu Glu Glu Leu Cys
65 70 75 80
His Glu Lys Glu Ile Leu Glu Lys Tyr Gly His Ssr Asp Cys Cys Ser
85 90 95
Gln Ser Glu Glu Gly Arg His Asn Cys Phe Leu Ala His Lys Lys Pro
100 105 110
Thr Ala Ala Trp Ile Pro Leu Phe Gln Val Pro Glu Pro Val Thr Ser
115 120 125
Cys Glu Ala Tyr Glu Glu Asp Arg Glu Thr Phe Met Asn Lys Phe Ile
130 135 140
Tyr Glu Ile Ala Arg Arg His Pro Phe Leu Tyr Ala Pro Thr Ile Leu
145 150 155 160
Leu Ser Ala Ala Gly Tyr Glu Lys Ile Ile Pro Ser Cys Cys Lys Ala
165 170 175
Glu Asn Ala Val Glu Cys Phe Gln Thr Lys Ala Ala Thr Val Thr Lys
180 185 190
Glu Leu Arg Glu Ser
195
(2) sequence 7 data:
(i) sequence signature:
(A) length: 192 aminoacid
(B) type: aminoacid
(C) chain: do not relate to
(D) topological structure: linearity
(ii) molecule type: albumen
(xi) sequence description: sequence 7
Ser Leu Leu Asn Gln His Ala Cys Pro Val Met Lys Asn Phe Gly Thr
1 5 10 15
Arg Thr Phe Gln Ala Ile Thr Val Thr Lys Leu Ser Gln Lys Phe Thr
20 25 30
Lys Val Asn Phe Thr Glu Ile Gln Lys Leu Val Leu Asp Val Ala His
35 40 45
Val His Glu His Cys Cys Arg Ala Asp Val Leu Asp Cys Leu Gln Asp
50 55 60
Gly Glu Lys Ile Met Ser Tyr Ile Cys Ser Gln Gln Asp Thr Leu Ser
65 70 75 80
Asn Lys Ile Thr Glu Cys Cys Lys Leu Thr Thr Leu Glu Arg Gly Gln
85 90 95
Cys Ile Ile His Ala Glu Asn Asp Glu Lys Pro Glu Gly Leu Ser Pro
100 105 110
Asn Leu Asn Arg Phe Leu Gly Asp Arg Asp Phe Asn Gln Phe Ser Ser
115 120 125
Gly Glu Lys Asn Ile Phe Leu Ala Ser Phe Val His Glu Tyr Ser Arg
130 135 140
Arg His Pro Gln Leu Ala Val Ser Val Ile Leu Arg Val Ala Lys Gly
145 150 155 160
Tyr Gln Glu Leu Leu Glu Lys Cys Phe Gln Thr Glu Asn Pro Leu Glu
165 170 175
Cys Gln Asp Lys Gly Glu Glu Glu Leu Gln Lys Tyr Ile Gln Glu Ser
180 185 190
(2) sequence 8 data:
(i) sequence signature:
(A) length: 201 aminoacid
(B) type: aminoacid
(C) chain: do not relate to
(D) topological structure: linearity
(ii) molecule type: albumen
(xi) sequence description: sequence 8
Gln Ala Leu Ala Lys Arg Ser Cys Gly Leu Phe Gln Lys Leu Gly Glu
1 5 10 15
Tyr Tyr Leu Gln Asn Glu Phe Leu Val Ala Tyr Thr Lys Lys Ala Pro
20 25 30
Gln Leu Thr Ser Ser Glu Leu Met Ala Ile Thr Arg Lys Met Ala Ala
35 40 45
Thr Ala Ala Thr Cys Cys Gln Leu Ser Glu Asp Lys Leu Leu Ala Cys
50 55 60
Gly Glu Gly Ala Ala Asp Ile Ile Ile Gly His Leu Cys Ile Arg His
65 70 75 80
Glu Met Thr Pro Val Asn Pro Gly Val Gly Gln Cys Cys Thr Ser Ser
85 90 95
Tyr Ala Asn Arg Arg Pro Cys Phe Ser Ser Leu Val Val Asp Glu Thr
100 105 110
Tyr Val Pro Pro Ala Phe Ser Asp Asp Lys Phe Ile Phe His Lys Asp
115 120 125
Leu Cys Gln Ala Gln Gly Val Ala Leu Gln Arg Met Lys Gln Glu Phe
130 135 140
Leu Ile Ash Leu Val Lys Gln Lye Pro Gln Ile Thr Glu Glu Gln Leu
145 150 155 160
Glu Ala Leu Ile Ala Asp Phe Ser Gly Leu Leu Glu Lys Cys Cys Gln
165 170 175
Gly Gln Glu Gln Glu Val Cys Phe Ala Glu Glu Gly Gln Lys Leu Ile
180 185 190
Ser Lys Thr Gly Ala Ala Leu Gly Val
195 200
(2) sequence 9 data:
(i) sequence signature:
(A) length: 389 aminoacid
(B) type: aminoacid
(C) chain: do not relate to
(D) topological structure: linearity
(ii) molecule type: albumen
(xi) sequence description: sequence 9
Thr Leu His Arg Asn Glu Tyr Gly Ile Ala Ser Ile Leu Asp Ser Tyr
1 5 10 15
Gln Cys Thr Ala Glu Ile Ser Leu Ala Asp Leu Ala Thr Ile Phs Phe
20 25 30
Ala Gln Phe Val Gln Glu Ale Thr Tyr Lys Glu Val Ser Lys Met Vel
35 40 45
Lys Asp Ala Leu Thr Ala Ile Glu Lys Pro Thr Gly Asp Glu Gln Ser
50 55 60
Ser Gly Cys Leu Glu Asn Gln Leu Pro Ala Phe Leu Glu Glu Leu Cys
65 70 75 80
His Glu Lys Glu Ile Leu Glu Lys Tyr Gly His Ser Asp Cys Cys Ser
85 90 95
Gln Ser Glu Glu Gly Arg His Asn Cys Phe Leu Ala His Lys Lys Pro
100 105 110
Thr Ala Ala Trp Ile Pro Leu Phe Gln Val Pro Glu Pro Val Thr Ser
115 120 125
Cys Glu Ala Tyr Glu Glu Asp Arg Glu Thr Phe Met Asn Lys Phe Ile
130 135 140
Tyr Glu Ile Ala Arg Arg His Pro Phe Leu Tyr Ala Pro Thr Ile Leu
145 150 155 160
Leu Ser Ala Ala Gly Tyr Glu Lys Ile Ile Pro Ser Cys Cys Lys Ala
165 170 175
Glu Asn Ala Val Glu Cys Phe Gln Thr Lys Ala Ala Thr Val Thr Lys
180 185 190
Glu Leu Arg Glu Ser Ser Leu Leu Asn Gln His Ala Cys Pro Val Met
195 200 205
Lys Asn Phe Gly Thr Arg Thr Phe Gln Ala Ile Thr Val Thr Lys Leu
210 215 220
Ser Gln Lys Phe Thr Lys Val Aan Phe Thr Glu Ile Gln Lys Leu Val
225 230 235 240
Leu Asp Val Ala His Val His Glu His Cys Cys Arg Ala Asp Val Leu
245 250 255
Asp Cys Leu Gln Asp Gly Glu Lys Ile Met Ser Tyr Ile Cys Ser Gln
260 265 270
Gln Asp Thr Leu Ser Asn Lys Ile Thr Glu Cys Cys Lys Leu Thr Thr
275 280 285
Leu Glu Arg Gly Gln Cys Ile Ile His Ala Glu Asn Asp Glu Lys Pro
290 295 300
Glu Gly Leu Ser Pro Asn Leu Asn Arg Phe Leu Gly Asp Arg Asp Phe
305 310 315 320
Asn Gln Phe Ser Ser Gly Glu Lys Asn Ile Phe Leu Ala Ser Phe Val
325 330 335
His Glu Tyr Ser Arg Arg His Pro Gln Leu Ala Val Ser Val Ile Leu
340 345 350
Arg Val Ala Lys Gly Tyr Gln Glu Leu Leu Glu Lys Cys Phe Gln Thr
355 360 365
Glu Asn Pro Leu Glu Cys Gln Asp Lys Gly Glu Glu Glu Leu Gln Lys
370 375 380
Tyr Ile Gln Glu Ser
385
(2) sequence 10 data:
(i) sequence signature:
(A) length: 393 aminoacid
(B) type: aminoacid
(C) chain: do not relate to
(D) topological structure: linearity
(ii) molecule type: albumen
(xi) sequence description: sequence 10
Ser Leu Leu Asn Gln His Ala Cys Pro Val Met Lys Asn Phe Gly Thr
1 5 10 15
Arg Thr Phe Gln Ala Ile Thr Val Thr Lys Leu Ser Gln Lys Phe Thr
20 25 30
Lys Val Asn Phe Thr Glu Ile Gln Lys Leu Val Leu Asp Val Ala His
35 40 45
Val His Glu His Cys Cys Arg Ala Asp Val Leu Asp Cys Leu Gln Asp
50 55 60
Gly Glu Lys Ile Met Ser Tyr Ile Cys Ser Gln Gln Asp Thr Leu Ser
65 70 75 80
Asn Lys Ile Thr Glu Cys Cys Lys Leu Thr Thr Leu Glu Arg Gly Gln
85 90 95
Cys Ile Ile His Ala Glu Asn Asp Glu Lys Pro Glu Gly Leu Ser Pro
100 105 110
Asn Leu Asn Arg Phe Leu Gly Asp Arg Asp Phe Asn Gln Phe Ser Ser
115 120 125
Gly Glu Lys Asn Ile Phe Leu Ala Ser Phe Val His Glu Tyr Ser Arg
130 135 140
Arg His Pro Gln Leu Ala Val Ser Val Ile Leu Arg Val Ala Lys Gly
145 150 155 160
Tyr Gln Glu Leu Leu Glu Lys Cys Phe Gln Thr Glu Asn Pro Leu Glu
165 170 175
Cys Gln Asp Lys Gly Glu Glu Glu Leu Gln Lys Tyr Ile Gln Glu Ser
180 185 190
Gln Ala Leu Ala Lys Arg Ser Cys Gly Leu Phe Gln Lys Leu Gly Glu
195 200 205
Tyr Tyr Leu Gln Asn Glu Phe Leu Val Ala Tyr Thr Lys Lys Ala Pro
210 215 220
Gln Leu Thr Ser Ser Glu Leu Met Ala Ile Thr Arg Lys Met Ala Ala
225 230 235 240
Thr Ala Ala Thr Cys Cys Gln Leu Ser Glu Asp Lys Leu Leu Ala Cys
245 250 255
Gly Glu Gly Ala Ala Asp Ile Ile Ile Gly His Leu Cys Ile Arg His
260 265 270
Glu Met Thr Pro Val Asn Pro Gly Val Gly Gln Cys Cys Thr Ser Ser
275 280 285
Tyr Ala Asn Arg Arg Pro Cys Phe Ser Ser Leu Val Val Asp Glu Thr
290 295 300
Tyr Val Pro Pro Ala Phe Ser Asp Asp Lys Phe Ile Phe His Lys Asp
305 310 315 320
Leu Cys Gln Ala Gln Gly Val Ala Leu Gln Arg Met Lys Gln Glu Phe
325 330 335
Leu Ile Asn Leu Val Lys Gln Lys Pro Gln Ile Thr Glu Glu Gln Leu
340 345 350
Glu Ala Leu Ile Ala Asp Phe Ser Gly Leu Leu Glu Lys Cys Cys Gln
355 360 365
Gly Gln Glu Gln Glu Val Cys Phe Ala Glu Glu Gly Gln Lys Leu Ile
370 375 380
Ser Lys Thr Gly Ala Ala Leu Gly Val
385 390
(2) sequence 11 data:
(i) sequence signature:
(A) length: 325 aminoacid
(B) type: aminoacid
(C) chain: do not relate to
(D) topological structure: linearity
(ii) molecule type: albumen
(xi) sequence description: sequence 11
Met Ser Tyr Ile Cys Ser Gln Gln Asp Thr Leu Ser Asn Lys Ile Thr
1 5 10 15
Glu Cys Cys Lys Leu Thr Thr Leu Glu Arg Gly Gln Cys Ile Ile His
20 25 30
Ala Glu Asn Asp Glu Lys Pro Glu Gly Leu Ser Pro Asn Leu Asn Arg
35 40 45
Phe Leu Gly Asp Arg Asp Phe Asn Gln Phe Ser Ser Gly Glu Lys Asn
50 55 60
Ile Phe Leu Ala Ser Phe Val His Glu Tyr Ser Arg Arg His Pro Gln
65 70 75 80
Leu Ala Val Ser Val Ile Leu Arg Val Ala Lys Gly Tyr Gln Glu Leu
85 90 95
Leu Glu Lys Cys Phe Gln Thr Glu Asn Pro Leu Glu Cys Gln Asp Lys
100 105 110
Gly Glu Glu Glu Leu Gln Lys Tyr Ile Gln Glu Ser Gln Ala Leu Ala
115 120 125
Lys Arg Ser Cys Gly Leu Phe Gln Lys Leu Gly Glu Tyr Tyr Leu Gln
130 135 140
Asn Glu Phe Leu Val Ala Tyr Thr Lys Lys Ala Pro Gln Leu Thr Ser
145 150 155 160
Ser Glu Leu Met Ala Ile Thr Arg Lys Met Ala Ala Thr Ala Ala Thr
165 170 175
Cys Cys Gln Leu Ser Glu Asp Lys Leu Leu Ala Cys Gly Glu Gly Ala
180 185 190
Ala Asp Ile Ile Ile Gly His Leu Cys Ile Arg His Glu Met Thr Pro
195 200 205
Val Asn Pro Gly Val Gly Gln Cys Cys Thr Ser Ser Tyr Ala Asn Arg
210 215 220
Arg Pro Cys Phe Ser Ser Leu Val Val Asp Glu Thr Tyr Val Pro Pro
225 230 235 240
Ala Phe Ser Asp Asp Lys Phe Ile Phe His Lys Asp Leu Cys Gln Ala
245 250 255
Gln Gly Val Ala Leu Gln Arg Met Lys Gln Glu Phe Leu Ile Asn Leu
260 265 270
Val Lys Gln Lys Pro Gln Ile Thr Glu Glu Gln Leu Glu Ala Leu Ile
275 280 285
Ala Asp Phe Ser Gly Leu Leu Glu Lys Cys Cys Gln Gly Gln Glu Gln
290 295 300
Glu Val Cys Phe Ala Glu Glu Gly Gln Lys Leu Ile Ser Lys Thr Gly
305 310 315 320
Ala Ala Leu Gly Val
325
(2) sequence 12 data:
(i) sequence signature:
(A) length: 324 aminoacid
(B) type: aminoacid
(C) chain: do not relate to
(D) topological structure: albumen
(ii) molecule type: albumen
(xi) sequence description: sequence 12
Ser Tyr Ile Cys Ser Gln Gln Asp Thr Leu Ser Asn Lys Ile Thr Glu
1 5 10 15
Cys Cys Lys Leu Thr Thr Lsu Glu Arg Gly Gln Cys Ile Ile His Ala
20 25 30
Glu Asn Asp Glu Lys Pro Glu Gly Leu Ser Pro Asn Leu Asn Arg Phe
35 40 45
Leu Gly Asp Arg Asp Phe Asn Gln Phe Ser Ser Gly Glu Lys Asn Ile
50 55 60
Phe Leu Ala Ser Phe Val His Glu Tyr Ser Arg Arg His Pro Gln Leu
65 70 75 80
Ala Val Ser Va1 Ile Leu Arg Val Ala Lys Gly Tyr Gln Glu Leu Leu
85 90 95
Glu Lys Cys Phe Gln Thr Glu Asn Pro Leu Glu Cys Gln Asp Lys Gly
100 105 110
Glu Glu Glu Leu Gln Lys Tyr Ile Gln Glu Ser Gln Ala Leu Ala Lys
115 120 125
Arg Ser Cys Gly Leu Phe Gln Lys Leu Gly Glu Tyr Tyr Leu Gln Aan
130 135 140
Glu Phe Leu val Ala Tyr Thr Lys Lys Ala Pro Gln Leu Thr Ser Ser
145 150 155 160
Glu Leu Met Ala Ile Thr Arg Lys Met Ala Ala Thr Ala Ala Thr Cys
165 170 175
Cys Gln Leu Ser Glu Asp Lys Leu Leu Ala Cys Gly Glu Gly Ala Ala
180 185 190
Asp Ile Ile Ile Gly His Leu Cys Ile Arg His Glu Met Thr Pro Val
195 200 205
Asn Pro Gly Val Gly Gln Cys Cys Thr Ser Ser Tyr Ala Asn Arg Arg
210 215 220
Pro Cys Phe Ser Ser Leu Val Val Asp Glu Thr Tyr Val Pro Pro Ala
225 230 235 240
Phe Ser Asp Asp Lys Phe Ile Phe His Lys Asp Leu Cys Gln Ala Gln
245 250 255
Gly Val Ala Leu Gln Arg Met Lys Gln Glu Phe Leu Ile Asn Leu Val
260 265 270
Lys Gln Lys Pro Gln Ile Thr Glu Glu Gln Leu Glu Ala Leu Ile Ala
275 280 285
Asp Phe Ser Gly Leu Leu Glu Lys Cys Cys Gln Gly Gln Glu Gln Glu
290 295 300
Val Cys Phe Ala Glu Glu Gly Gln Lys Leu Ile Ser Lys Thr Gly Ala
305 310 315 320
Ala Leu Gly Val
(2) sequence 13 data:
(i) sequence signature:
(A) length: 9 aminoacid
(B) type: aminoacid
(C) chain: do not relate to
(D) topological structure: linearity
(ii) molecule type: albumen
(xi) sequence description: sequence 13
Ser Tyr Ile Cys Ser Gln Gln Asp Thr
1 5
(2) sequence 14 data:
(i) sequence signature:
(A) length: 30 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological structure: linearity
(ii) molecule type: DNA (genome)
(xi) sequence description: sequence 14
AAAAAAGGTA CCACACTGCA TAGAAATGAA
(2) sequence 15 data:
(i) sequence signature:
(A) length: 33 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological structure: linearity
(ii) molecule type: DNA (genome)
(xi) sequence description: sequence 15
AAAAAAGGAT CCTTAGCTTT CTCTTAATTC TTT
(2) sequence 16 data:
(i) sequence signature:
(A) length: 33 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological structure: linearity
(ii) molecule type: DNA (genome)
(xi) sequence description: sequence 16
AAAAAATCG ATATGAGCTT GTTAAATCAA CAT
(2) sequence 17 data:
(i) sequence signature:
(A) length: 33 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological structure: linearity
(ii) molecule type: DNA (genome)
(xi) sequence description: sequence 17
AAAAAAGGAT CCTTAGCTCT CCTGGATGTA TTT
(2) sequence 18 data:
(i) sequence signature:
(A) length: 33 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological structure: linearity
(ii) molecule type: DNA (genome)
(xi) sequence description: sequence 18
AAAAAAATCG ATATGCAAGC ATTGGCAAAG CGA
(2) sequence 19 data:
(i) sequence signature:
(A) length: 33 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological structure: linearity
(ii) molecule type: DNA (genome)
(xi) sequence description: sequence 19
AAAAAAGGAT CCTTAAACTC CCAAAGCAGC ACG
(2) sequence 20 data:
(i) sequence signature:
(A) length: 33 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological structure: linearity
(ii) molecule type: DNA (genome)
(xi) sequence description: sequence 20
AAAAAAATCG ATATGTCCTA CATATGTTCT CAA
(2) sequence 21 data:
(i) sequence signature:
(A) length: 21 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological structure: linearity
(ii) molecule type: DNA (genome)
(xi) sequence description: sequence 21
GATCTAGAAT TCGGATCCGG T
(2) sequence 22 data:
(i) sequence signature:
(A) length: 10 aminoacid
(B) type: aminoacid
(C) chain: do not relate to
(D) topological structure: linearity
(ii) molecule type: albumen
(xi) sequence description: sequence 22
Asp Leu Glu Phe Met Thr Leu His Arg Asn
1 5 10
(2) sequence 23 data:
(i) sequence signature:
(A) length: 32 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological structure: linearity
(ii) molecule type: DNA (genome)
(xi) sequence description: sequence 23
AAAAAACTCG AGATACACTG CATAGAAATG AA
(2) sequence 24 data:
(i) sequence signature:
(A) length: 33 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological structure: linearity
(ii) molecule type: DNA (genome)
(xi) sequence description: sequence 24
AAAAAAGAAT TCTTAAACTC CCAAAGCAGC ACG

Claims (26)

1. recombinant human alpha-fetoprotein or its comprise the purposes of fragment in the preparation medicine of domain I, domain II, domain II I, domain I+II, domain II+III or fragment I, and described medicine is used for:
A) propagation of id reaction type immunocyte in the inhibition mammal;
B) autoimmune disease in the treatment mammal;
C) tumor in the inhibition mammal;
D) the prevention mammal produces tumor;
E) suppress mammiferous myelotoxicity;
F) suppress the effect of mammal medullary cell inhibition of proliferation;
G) promote mammal medullary cell propagation; Or
H) prevent the graft-rejection of medullary cell in the mammal.
2. the purposes of claim 1, wherein, described mammal is a human patients.
3. the purposes of claim 1, wherein, described reorganization alpha-fetoprotein or its fragment are produced by prokaryotic cell and are not by glycosylated.
4. the purposes of claim 3, wherein, described prokaryotic cell is escherichia coli.
5. the purposes of claim 1, wherein, described immunocyte comprises the T cell.
6. the purposes of claim 1, wherein, described immunocyte comprises the B cell.
7. the purposes of claim 1, wherein said medicine is used to suppress id reaction type immune cell propagation, and comprises the immunosuppressant of effective dose, and described dosage is lower than the standard dose of the described immunosuppressant of independent use.
8. the purposes of claim 7, wherein, described immunosuppressant is a cyclosporin.
9. the purposes of claim 7, wherein, described immunosuppressant is steroid, azathioprine, FK-506 or 15-deoxyspergualin.
10. the purposes of claim 1, wherein said medicine also comprises a kind of tolerance agent.
11. the purposes of claim 1, wherein, described autoimmune disease is a multiple sclerosis.
12. the purposes of claim 1, wherein, described autoimmune disease is a rheumatoid arthritis.
13. the purposes of claim 1, wherein, described autoimmune disease is a myasthenia gravis.
14. the purposes of claim 1, wherein, described autoimmune disease is an insulin-dependent diabetes.
15. the purposes of claim 1, wherein, described autoimmune disease is a systemic lupus erythematosus (sle).
16. the purposes of claim 1, wherein, described tumor is a malignant tumor.
17. the purposes of claim 16, wherein, described malignant tumor is a breast carcinoma.
18. the purposes of claim 16, wherein said malignant tumor is a carcinoma of prostate.
19. the purposes of claim 1, wherein, described tumor is a cancer.
20. the purposes of claim 1, wherein, described tumor is an adenocarcinoma.
21. the purposes of claim 1, wherein said tumor is a sarcoma.
22. the purposes of claim 1, wherein, described tumor is bred in response to answering estrogen.
23. the purposes of claim 1, wherein, described medicine suppresses the cell proliferation of tumor described in the described mammal.
24. the purposes of claim 1, wherein, described medicine kills the cell of tumor described in the described mammal.
25. the purposes of claim 1, wherein said medicine is used to suppress tumor, and also comprises the standard dose the when chemotherapeutics of effective dose, described dosage are lower than the described chemotherapeutics of independent use.
26. the purposes of claim 1, wherein, a kind of receptor that can discern by described recombinant human alpha-fetoprotein or its fragment or analog of the cellular expression of described tumor.
CNB96192764XA 1995-01-24 1996-01-24 Recombinant human alpha-fetoprotein and uses thereof Expired - Lifetime CN1150030C (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US37731695A 1995-01-24 1995-01-24
US37731795A 1995-01-24 1995-01-24
US37731195A 1995-01-24 1995-01-24
US08/377,309 US5965528A (en) 1991-09-27 1995-01-24 Recombinant human alph-fetoprotein as an immunosuppressive agent
US08/505,012 US6331611B1 (en) 1991-09-27 1995-07-21 Expression and purification of cloned human alpha-fetoprotein
US08/377,317 1995-07-21
US08/377,309 1995-07-21
US08/377,316 1995-07-21
US08/377,311 1995-07-21
US08/505,012 1995-07-21

Publications (2)

Publication Number Publication Date
CN1179106A CN1179106A (en) 1998-04-15
CN1150030C true CN1150030C (en) 2004-05-19

Family

ID=27541364

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB96192764XA Expired - Lifetime CN1150030C (en) 1995-01-24 1996-01-24 Recombinant human alpha-fetoprotein and uses thereof

Country Status (7)

Country Link
EP (1) EP0805687A4 (en)
JP (2) JPH10513347A (en)
CN (1) CN1150030C (en)
AU (1) AU700975B2 (en)
CA (1) CA2211324C (en)
HK (1) HK1010153A1 (en)
WO (1) WO1996022787A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965528A (en) 1991-09-27 1999-10-12 Mcgill University Recombinant human alph-fetoprotein as an immunosuppressive agent
US6288034B1 (en) 1995-01-24 2001-09-11 Martinex R & D Inc. Recombinant human alpha-fetoprotein as an immunosuppressive agent
WO2001058922A2 (en) * 2000-02-10 2001-08-16 The Regents Of The University Of California Method and compositions for treating hepatocellular cancer
US7098306B2 (en) 1997-02-13 2006-08-29 The Regents Of The University Of California Method and compositions for treating hepatocellular cancer
KR100460583B1 (en) * 1997-02-13 2004-12-08 더 리전츠 오브 더 유니버시티 오브 캘리포니아 Prevention and treatment of hepatocellular cancer
US7208576B2 (en) 1999-01-06 2007-04-24 Merrimack Pharmaceuticals, Inc. Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof
EP1958503A3 (en) * 1999-01-06 2008-11-26 Merrimack Pharmaceuticals, Inc. Expression of secreted human alpha-fetoprotein in transgenic animals
US7022892B1 (en) 1999-07-12 2006-04-04 Universite Libre De Bruxelles Non-human genetically modified mammal lacking the alpha-fetoprotein
ATE418607T1 (en) * 1999-07-12 2009-01-15 Univ Bruxelles GENETICALLY MODIFIED NON-HUMAN ANIMAL DEFECTIVE IN ALPHA-FETOPROTEIN
FI118263B (en) * 2002-10-09 2007-09-14 Timo Kalevi Korpela Peptides that regulate caspase activity
US7074561B2 (en) * 2002-10-22 2006-07-11 Biomerieux, Inc. Isothermal amplification based assay for the detection and quantitation of alpha-fetoprotein mRNA
WO2006031611A1 (en) * 2004-09-09 2006-03-23 Serometrix Llc Compositions and methods of using alpha-fetoprotein growth inhibitory peptides
US8932829B2 (en) 2005-07-07 2015-01-13 Elena Dudich Recombinant alpha-fetoprotein and compositions thereof
GB0617564D0 (en) * 2006-09-06 2006-10-18 Ucl Business Plc Peptides and methods
AU2007338771A1 (en) * 2006-12-19 2008-07-03 Merrimack Pharmaceuticals, Inc. Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
WO2008113970A2 (en) * 2007-03-16 2008-09-25 Ucl Business Plc Peptides
CN105732795A (en) * 2016-03-21 2016-07-06 海南医学院 Method for acquiring human alpha fetoproteins
CN112898399A (en) * 2019-12-03 2021-06-04 香雪生命科学技术（广东）有限公司 Short peptides derived from AFP antigens
CN113416729B (en) * 2021-05-18 2022-11-22 遵义医科大学附属医院 shRNA and cDNA of liver target regulation alpha fetoprotein gene and application thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5486602A (en) * 1977-10-27 1979-07-10 Hoffmann La Roche Production of purified alpha 1 phetoprotein
JPH025866A (en) * 1988-06-27 1990-01-10 Kansai Shin Gijutsu Kenkyusho:Kk Human alha fetoprotein domain i gene, corresponding plasmid, corresponding transformant, production of said domain i and produced said domain i
IT1226551B (en) * 1988-07-29 1991-01-24 Sclavo Spa IMMUNOLOGICALLY ACTIVE SYNTHETIC PEPTIDE CAPABLE OF INDUCING THE PRODUCTION OF ANTIBODIES WITH HIGH SPECIFICITY TOWARDS ALPHA-PHETOPROTEIN AND THEIR USE IN THE DIAGNOSTIC FIELD
EP0356399A3 (en) * 1988-08-26 1991-03-20 Sandoz Ag Substituted 4-azatricyclo (22.3.1.04.9) octacos-18-ene derivatives, their preparation and pharmaceutical compositions containing them
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
US5206153A (en) * 1990-06-27 1993-04-27 Snow Brand Milk Products Co., Ltd. Method of producing human α-fetoprotein and product produced thereby
WO1993005774A1 (en) * 1991-09-25 1993-04-01 Wisconsin Alumni Research Foundation Complexes of anthracycline antibiotics with polyunsaturated fatty acids in lipid emulsions
CA2120131A1 (en) * 1991-09-27 1994-05-11 Robert A. Murgita Expression and purification of cloned human alpha-fetoprotein
EP0783714B1 (en) * 1994-09-26 2001-11-28 Infineon Technologies AG Optical coupler designed to couple an oeic module to optical fibres

Also Published As

Publication number Publication date
CA2211324C (en) 2012-07-10
AU700975B2 (en) 1999-01-14
AU4903596A (en) 1996-08-14
EP0805687A4 (en) 2000-05-31
CA2211324A1 (en) 1996-08-01
HK1010153A1 (en) 1999-06-17
JP2008073041A (en) 2008-04-03
EP0805687A1 (en) 1997-11-12
CN1179106A (en) 1998-04-15
WO1996022787A1 (en) 1996-08-01
JPH10513347A (en) 1998-12-22

Similar Documents

Publication Publication Date Title
CN1150030C (en) Recombinant human alpha-fetoprotein and uses thereof
CN1161152C (en) Method and compositions useful for inhibition of angiogenesis
CN1217956C (en) Soluble single-chain T-cell receptor proteins
CN1649895A (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
CN1549826A (en) Compositions and methods of treating diabetes
CN1599754A (en) Anti-TRAIL-R antibodies
CN1130372C (en) Peptide derivatives
CN1543476A (en) Methods and compounds for the targeting of protein to exosomes
CN1216994A (en) Apoptosis inducing molecule II
CN1589279A (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
CN1201003C (en) Adipocyte-specific protein homologs
CN1561343A (en) Soluble T cell receptor
CN1817901A (en) Therapeutic peptides and method
CN1845995A (en) Chimeric antigens for breaking host tolerance to foreign antigens
CN1675362A (en) HLA-A24-restricted cancer antigen peptide
CN1272884A (en) Adipocyte-specific protein homologs
CN1096032A (en) New active compound
CN1275085A (en) Cytolysis of target cell, reagent and composition for cytolysis and compound for preparing these reagents
CN1582301A (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
CN1116305C (en) Peptide derivatives
CN1090510A (en) Interferon constituent and uses thereof
CN1133049A (en) Melanona-inhibiting protein
CN1527723A (en) Methods for treating or preventing skin disorders using CD2-binding agents
CN1723032A (en) Compositions and methods for modifying toxic effects of proteinaceous compounds
CN1170933C (en) Motilin homologs

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: MATTIE KNICKS RESEARCH AND DEVELOPMENT CO., LTD.

Free format text: FORMER OWNER: MCGILL UNIVERSITY

Effective date: 20030709

Owner name: MCGILL UNIVERSITY

Free format text: FORMER OWNER: ROBERT A MOJITA

Effective date: 20030709

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20030709

Address after: Canada Quebec

Applicant after: MURGITA, ROBERT A.

Address before: Montreal, Canada

Applicant before: MCGILL University

Effective date of registration: 20030709

Address after: Montreal, Canada

Applicant after: MCGILL University

Address before: Montreal, Canada

Applicant before: Robert A. Murgita

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1010153

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: MERRIMAC MEDICINE CO., LTD.

Free format text: FORMER OWNER: MATTIE KNICKS RESEARCH AND DEVELOPMENT CO., LTD.

Effective date: 20061208

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20061208

Address after: Massachusetts, USA

Patentee after: MERRIMACK PHARMACEUTICALS Inc.

Address before: Quebec

Patentee before: MURGITA, ROBERT A.

CX01 Expiry of patent term

Granted publication date: 20040519

EXPY Termination of patent right or utility model